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Abstract 
Osteoarthritis (OA) is the most common musculoskeletal disorder with 
inflammatory, metabolic and mechanical causes. Its aetiology is largely unknown; 
however, it is multi-factorial and by a variety of means reaches a common end stage 
of joint destruction. Regardless of the aetiology, the disease is progressive and is 
characterised by a series of predictable clinical and radiological changes. One of the 
earliest radiological changes seen, often before any joint space narrowing is 
observed, is subchondral bone sclerosis [1]. Signs of abnormal subchondral bone 
mineral density and enhanced production of bone turnover markers have been 
demonstrated and are indicative of bone cell dysfunction in osteoblasts [2] and 
osteoclasts [3] with no consideration given to osteocytes (90% of the bone cells). 
Exciting discoveries in recent years have changed the idea of osteocytes from being 
passive, metabolically inactive cells to endocrine cells and orchestrators of bone 
remodelling, representing a paradigm shift in the bone research field. Regardless of 
whether subchondral bone sclerosis is the initiating or secondary event, it is a 
consistent finding in OA but its significance, particularly the role of osteocyte cells 
in this disease progression, has only received limited attention. 
The aim of this project was to evaluate the subchondral bone and mineral 
changes and address the question of how the most abundant and longest lived bone 
cell type, “osteocyte”, changes in the pathology of OA. This was achieved in three 
studies. The first study focused on characterising the sclerotic and non-sclerotic 
subchondral bone area from clinical samples. Based on the clinical findings, a 
suitable small animal model (rat medial menisectomy) that resembles the clinical 
subchondral bone situation was then established as the second study to further 
understand the osteocyte and mineral changes during OA pathophysiology. Further, 
in an attempt to explain the clinical and animal model findings from an osteocyte 
perspective and gain an insight into the underlying mechanisms controlling the 
observed changes, for the third study, a series of in vitro studies were undertaken. 
Involvement of WNT signalling pathway was evaluated in an OA environment (low-
dose inflammation).  
 Phenotypical Changes of Osteocytes in Osteoarthritis v 
The first study involved the examination of human bone samples collected 
from the knees of OA patients undergoing knee replacement surgery. The 
subchondral bone mineral properties and phenotypic characteristics of the osteocyte 
network were characterised by determining changes in osteocyte morphology, 
distribution and apoptosis as well as evaluating the expression of osteocyte markers 
and matrix degradation enzymes. This study demonstrated that OA samples had 
altered osteocyte morphology and dysregulated osteocytic protein expression with 
hampered mineral metabolism compared to controls. It was postulated that the 
phenotypic changes of osteocytes in OA patients are responsible for the active site-
specific remodelling of subchondral bone, resulting in subchondral bone thickening 
and dysregulated mineral metabolism. 
Based on the findings obtained from clinical samples from study one, the 
second study involved establishing an animal model to further investigate the focal 
mineral and osteocyte changes. For this purpose, OA was induced in twelve week old 
Wistar Kyoto rats by the removal of the medial meniscus. Subchondral bone mineral 
properties, bone remodelling rate and osteocyte changes were investigated and 
characterised. Using this model, we demonstrated and defined the mineral and 
osteocyte changes observed clinically and showed that the OA menisectomy 
experimental rat model resembled the human situation  closely making it suitable for 
the study of OA subchondral bone osteocyte pathogenesis. Based on the finding, it 
was proposed, that osteocytes play a role in this process where there is increased 
focal bone remodelling with net bone formation associated with hampered mineral 
metabolism. The role of osteocyte WNT β-catenin signalling pathway was also 
investigated.  
The third study considered a series of in vitro studies. Along with subchondral 
bone sclerosis, an increased number of migratory inflammatory cells and the 
substances secreted by these cells have been recognised in the OA joint tissues. This 
is not nearly as prominent as in the case of rheumatoid arthritis, which is clearly an 
autoimmune disease, but enough to speculate that inflammation plays a role in OA. 
Increasing evidence indicates that tumour necrosis factor α (TNFα) has an important 
role not only in inflammatory arthritis but also in OA [4]. The use of Anti-TNFα has 
been shown as a promising therapeutic strategy for the treatment of OA [5], however 
its mechanisms are unexplored and debated. To explain the question of balance in 
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bone remodelling and changes to osteocytes in an OA environment (low-dose 
inflammation), an in vitro model was set up using an osteocyte cell line, MLOY4. 
Interesting and unexpected outcomes demonstrated that osteocytes exposed to low-
dose long-term inflammation (TNFα), promoted bone formation via WNT β-catenin 
signalling while high-dose inflammation indicated bone resorption. We believe that 
osteocytes exposed to low-dose long-term inflammation could potentially promote 
subchondral bone sclerosis in OA.  
The three studies together demonstrate that the OA osteocyte phenotype exhibit 
distinctive changes that could be influenced by low-dose inflammation. These 
changes participate in OA subchondral bone sclerosis and/or pathogenesis via 
osteocyte WNT β-catenin signalling. The OA menisectomy experimental rat model 
could be used to further study the progression of subchondral bone osteocyte 
pathogenesis. Activation or deactivation of signalling molecules controlling 
osteocytes hold great potential to be a target for novel therapies. These may include 
activation/deactivation of osteocyte signalling molecules or osteocyte WNT β-
catenin signalling pathway molecules. 
In conclusion, respecting the limitations of this study, it is considered that this 
thesis characterises OA osteocytes (clinically, in vitro and in vivo) and provides a 
rational explanation for how OA osteocytes could play a role in subchondral bone 
sclerosis. The biological relevance of these results could further the effort towards 
achieving the ultimate goal of finding a therapeutic cure for OA. It is acknowledged 
that further investigations into the role of osteocytes in the development of OA are 
needed but this thesis provides a platform to understand the direction in which this 
research could be guided.  
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1.1 RESEARCH PROBLEM 
Osteoarthritis (OA) is one of the most common and oldest known 
musculoskeletal disorders, affecting more than 100 million individuals worldwide, 
representing a major health burden to society [6]. OA is a result of both mechanical 
and biological events that destabilise the normal coupling of degradation and 
synthesis of articular cartilage chondrocytes (ACCs), extracellular matrix (ECM) and 
subchondral bone. Although mechanical and biological events may be initiated by 
multiple factors, (including genetic, developmental, metabolic and traumatic) OA 
involves all tissues of the diathrodial joint associated with inflammation [7].  
Research into the aetiology of OA has mainly concentrated on the destruction of 
articular cartilage as the damage is clearly visible. In the course of OA development, 
ACCs undergo typical phenotypic changes characterised by the expression of 
hypertrophic differentiation markers, leading to irreversible cartilage degeneration. 
However, recently, several studies have shown that subchondral bone sclerosis plays 
an important role in the initiation and progression of OA [8, 9]. 
The subchondral bone consists of three types of bone cells; osteoblasts, 
osteoclasts and osteocytes.  Subchondral bone sclerosis is a well recognised 
manifestation of human OA, however, the mechanisms responsible for this are 
unknown [10]. The subchondral bone in OA shows signs of abnormal mineral 
density and enhanced production of bone turnover markers, indicative of osteoblast 
dysfunction [8, 11]. Osteoclasts are the cells that degrade bone to initiate normal 
bone remodelling, and mediate bone loss in pathologic conditions by increasing their 
resorptive activity [12]. With enormous knowledge/research available for osteoblasts 
and osteoclasts and their role in bone function and OA, it is now time to focus on 
osteocytes, as research in the last decade shows evidence that these cells are 
dynamic, have multiple functions and are vital for bone homeostasis [13, 14].  
Osteocytes represent 95 percent of all bone cells. These cells are terminally 
differentiated osteoblasts that occupy the lacunar space and are surrounded by the 
bone matrix. They possess cytoplasmic dendrites that form a canalicular network for 
communication between bone cells [15]. The role of osteocytes has remained 
unknown for a long time and has historically been underestimated [16]. Over the past 
10 years many publications have aimed to highlight the role of these cells in 
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homeostasis and various bone dysplasias.  Where osteoclasts, osteoblasts and lining 
cells are present at the bone surface, osteocytes are distinctive and isolated cells that 
are embedded within the bone matrix [15]. The difficulty in isolating these cells 
within the bone matrix may explain one of the initial reasons behind why they were 
ignored for so long.  Recent advances in bone biology have revealed that osteocytes  
cells play multiple functions in regulation of bone mineral density, cell 
differentiation and bone matrix composition, as well as act as an endocrine cell [14]. 
It is now evident that osteocytes play a central role in the maintenance of bone matrix 
homeostasis via their unique morphology and their canalicular cell network  [14, 15, 
17]. 
Substantial changes in the cartilage and subchondral bone associated with low-
dose inflammation are common in most of the patients suffering from OA [18, 19]. 
Much knowledge about the cartilage and bone structural changes are already known, 
but as yet, researchers have had little success in elucidating the pathogenesis of OA. 
The changes of the bone and cartilage in OA of the knee are more common in the 
medial compartment. As the subchondral bone and cartilage changes are 
synchronised, this indicates that the change in the cartilage are linked to the change 
in the bone during the development of OA. In certain animal models, synchronised 
changes in the subchondral bone and cartilage were observed during disease 
development [20]. It was also proposed that subchondral bone sclerosis precedes and 
contributes to cartilage damage [21]. However, a significant knowledge gap exists in 
understanding the role of osteocytes and the extent of their changes and their 
implications under normal and OA disease conditions. Therefore a new overall 
working hypothesis is necessary to better understand the stages involved in the 
progression of OA with respect to osteocytes. 
An increased number of migratory inflammatory cells and the substances 
secreted by them have been recognised in the OA joint tissues. This is not as 
prominent as in the case of rheumatoid arthritis, which is clearly an autoimmune 
disease, but enough to raise the question if inflammation also plays a role in the 
development OA. Secreted inflammatory molecules, such as proinflammatory 
cytokines like TNFα and IL-1β, are among the critical mediators of the disturbed 
processes implicated in OA pathophysiology, making them prime targets for 
therapeutic strategies [22]. A few clinical studies have investigated the efficacy of 
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blocking these proinflammatory cytokines in the treatment of OA in humans [23].  
Animal studies also provide evidence that it could be beneficial to slow the 
progression of OA [24]. To date, the mechanisms theat control the blocking of 
proinflammatory cytokines are unexplored and debatable[4]. Low-grade 
inflammation is detected in OA, it is viewed as a secondary phenomenon related to 
the destruction of cartilage [25]. Therefore, it would be of significant interest to test 
the effect of low-dose inflammation on osteocytes and how these changes could play 
a potential role in the degeneration of the subchondral bone in OA. 
The exact molecular mechanisms involved in the control of osteocytes in 
homeostasis and diseases like OA are yet to be investigated. Fully differentiated cells 
maintain their specialised character through signalling pathways, and amongst these 
signalling factors, secreted proteins from WNT β-catenin pathways are reported to 
regulate many critical fundamental biological factors [26].  The role of the WNT in 
bone formation and remodelling has been reviewed for over half a decade and its role 
in OA has been emphasised [27]. More recently, the osteocyte-WNT β-catenin 
pathway has been shown to be  a major signalling pathway required for 
mechanotransduction in bone in vivo [28]. It is also critical for normal bone 
homeostasis [29]. Given the importance of the WNT β-catenin pathway in cartilage 
and bone biology, and more specifically in osteocyte biology, the decision was made 
to investigate whether this pathway would play a role in the osteocyte OA 
pathophysiology.  
Driven by these issues, the overall aim of this thesis was to evaluate the 
subchondral bone and mineral changes and address the question of how the most 
abundant and longest lived bone cell type, “osteocyte”, changes in the pathology of 
OA. In order to accomplish this, subchondral bone and osteocytes were characterised 
in human OA samples. A clinically relevant in vivo model was established and the 
role of the osteocyte-WNT β-catenin pathway was defined. Various in vitro culture 
and co-culture models were set up to test the effect of low-dose inflammation on 
osteocytes to study their role in subchondral bone sclerosis.  
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1.2 HYPOTHESIS  
Osteocyte phenotypic changes play a role in OA subchondral bone sclerosis. 
1.3 SPECIFIC GOALS 
The specific aims of this thesis are summarized below 
1. Study the subchondral bone and osteocyte changes in the development of OA in 
bone collected from human OA joints (Chapter 3) 
2. Establish a clinically relevant small animal model to study the progression of 
subchondral bone, mineral and bone remodelling changes in OA (Chapter 4) 
3. Investigate the role of low-dose long-term inflammation (TNFα) on osteocytes 
(Chapter 5) 
4. Investigate the role of the osteocyte WNT β-catenin pathway in the pathogenesis 
of OA (Chapter 4 & 5) 
1.4 THESIS STRUCTURE 
This thesis consists of 7 chapters. The current chapter is a brief introduction, 
discussing the research problem, stating the hypothesis and summarising the main 
aims of the study. Chapter 2 provides a comprehensive literature review of the 
current understandings of the topics investigated (OA, subchondral bone, osteocytes 
and the WNT β-catenin signalling pathway). Chapter 3 is a published study 
characterising the OA osteocytes from sclerotic zones to study their pathological role 
in subchondral bone sclerosis. Chapter 4 is a recently submitted study involving the 
establishment of a clinically relevant animal model. It investigates the focal mineral 
and osteocyte changes and the involvement of the osteocyte-WNT β-catenin 
signalling pathway in a surgically induced OA rat model (medial menisectomy). 
Chapter 5 investigates the role of the osteocyte-WNT β-catenin pathway in long 
term, low-dose inflammation and its potential pathological role in OA. Chapter 6 
draws conclusions and discusses the studies in the preceding chapters to demonstrate 
novel additions to our understanding of the aetiology of OA and osteocyte biology. 
Limitations of this study and suggestions for future directions are discussed.Chapter 
7 presents supplementary data and some interesting images of the osteocyte network.
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2.1 OSTEOARTHRITIS: AN INTRODUCTION TO THE DISEASE 
2.1.1 History 
Osteoarthritis (OA) is the planet’s  oldest known disease found in the skeletons 
of dinosaurs (50-70 million years old), Egyptian mummies and in ancient skeletons 
found in England [30, 31]. In man, OA was found in different joints, however the 
frequency of affected knee joints was relatively less than observed in more recent 
times and this could probably be the consequence of modern factors and lifestyle. 
Despite its existence and early reference by Hippocrates (460-375 BC), clinicians did 
not formally recognise OA until the 18th century [30]. OA was originally grouped 
together with rheumatoid arthritis until the early 19th century; this created confusion 
in nomenclature and led to the delay in the recognition of the disease. In 1859 Alfred 
Baring Garrod separated the two diseases and proposed the name rheumatoid 
arthritis. John Kent Spender later introduced the term OA while in 1904, Joel E 
Goldthwait clearly differentiated the two diseases that were later confirmed by others 
in the field. Debate on the nomenclature of OA still continues to date. This is due to 
limited understanding of synovitis (synovial inflammation), and the aetiology of OA 
[32]. 
2.1.2 Epidemiology  
OA is the most common debilitating condition now accepted as a major 
public health problem (World Health Organisation). The prevalence of OA increases 
with age and is higher in women than in men, especially among the elderly. OA 
affects more than 1.6 million people in Australia and is a major cause of disability, 
psychological distress and poor quality of life. The total cost impact of OA in 
Australia was estimated to be almost $10.6 billion in 2007 and the prevalence of OA 
is projected to increase to 3.1 million people by 2040. This is driven by a range of 
factors including ageing of population and increasing rates of obesity (AIHW 2010). 
2.1.3 Pathogenesis, aetiology and symptoms  
         OA is defined by the American College of Rheumatology as:  
“Heterogeneous group of conditions that lead to joint symptoms and signs which are 
associated with defective integrity of articular cartilage, in addition to related 
changes in the underlying bone at the joint margins”.  
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OA of the knee is an incurable and debilitating musculoskeletal disorder of the entire 
joint. As OA progresses over decades, patients are asymptomatic in the early stages 
despite significant irreversible changes to bone structure. OA is the degeneration of 
articular cartilage, that serves as a "cushion" between the bones of the joint; together 
with changes in the subchondral bone [33]. Imbalance in this adaptation of the 
cartilage and bone is a result of various factors disturbing the physiological 
relationship between these tissues and contributes to the symptoms of OA. This 
includes pain, mild inflammation and joint stiffness [34]. The aetiology of OA is 
largely unknown and is multi-factorial with inflammatory, metabolic and mechanical 
causes leading to a common end stage. The risk factors that increase a person’s 
chance of developing OA  include genetic factors, obesity, injury, joint overuse and 
other diseases.  
2.1.4 Treatment and therapy 
At present, there is no cure for OA. The principal treatment objectives are to 
control pain adequately, improve function and reduce disability [33]. Early detection 
and management of OA can help reduce long-term damage; however, patients most 
often notice symptoms of pain and discomfort at the later or end stage of OA 
development. At present, the goal of every treatment for arthritis is to reduce pain 
and stiffness, allow for greater mobility and slow the progression of the 
disease. Non-Steroidal Anti Inflammatory Drugs (NSAIDS) and analgesics are used 
as symptomatic treatment to reduce inflammation and pain [35-37]. Glucosamine 
sulphate (GS) and chondroitin sulphate (CS) are derivatives of glycosaminoglycans 
found in articular cartilage. Some patients report the effectiveness of this analgesic 
for the relief of pain in OA [38-40]. Some studies with varying levels of evidence 
suggest that sodium hyaluronan, doxycycline, matrix metalloproteinase (MMP) 
inhibitors, bisphosphonates, calcitonin, diacerein, cyclo-oxygenase 2 specific 
inhibitors (CSIs) and avocado-soybean unsaponifiables may modify disease 
progression [41, 42]. The OARSI OA treatment guidelines provide useful list of 
interventions that have been proved to be effective in improving OA pain. It also 
provides Non-pharmacological management strategies include education and 
intervention, weight loss, exercise, physiotherapy and mechanical aids [43]. In the 
event that non-surgical therapies fail and joint degeneration advances, joint 
prosthesis surgery is required. 
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2.2 JOINTS 
Joints are areas where two bones meet. There are three different types of joints 
classified by the degree of movement. These are: Synarthroses - immovable joints 
like skull bones and the distal tibiofibular joint; Amphiarthroses - slightly moveable 
joints like the vertebrae, and Diarthroses /diathrodial joints that are freely movable. 
They have numerous components including synovium, synovial fluid, capsule, 
hyaline cartilage and bone. Together, these components work in a synchronised 
manner to facilitate movements of the body. Muscles and bones are connected via 
tendons and ligaments stabilising the joint. To minimise friction, lining cells of the 
synovial membrane secrete synovial fluid that acts as a lubricating and nourishing 
fluid. Articular cartilage provides a smooth surface that allows easy movement with 
minimal friction and wear. Mechanical support during loading is provided by 
subchondral and cancellous bone (located below the cartilage). The cartilage and the 
bone tissues have distinct properties that are both mechanical and biochemical [44, 
45] . 
2.3 ARTICULAR CARTILAGE  
 Cartilage is a tough yet flexible, highly specialised connective tissue that 
covers joints in the body. It has distinct biochemical and mechanical properties to 
maintain joint structure and allow for smooth, friction free movement. Figure 2-1 
shows the structure of human adult articular cartilage. 
2.3.1 Formation, structure and homeostasis of articular cartilage  
Mesenchymal stem cells that reside in the bone marrow differentiate into 
chondrogenic, myogenic  and osteogenic lineages under specific environmental cues’ 
that determine the differentiation of cartilage centrally, muscle peripherally, and 
bone [46]. The surrounding tissues, particularly the epithelium, influence the 
differentiation of mesenchymal progenitor cells to chondrocytes in cartilage 
anlagen[46]. This process can be divided into two phases. During the first phase, 
mesenchymal stem cells condense and undergo chondrogenic differentiation. In the 
second phase, a cartilaginous interzone appears, specifying the joint structure [47, 
48]. As development continues the interzone becomes a clearly distinguishable three-
zoned structure. While articular cartilage primarily is composed  of water, the solid 
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fraction predominantly consists of collagen fibers, aggrecan and other proteoglycans. 
The ultrastructure of articular cartilage can be divided into different zones where the 
functional properties of chondrocytes and the composition of ECM is different [49]. 
Articular cartilage is avascular; therefore the chondrocytes get nourished by diffusion 
from the synovial fluid and the vasculature of the subchondral bone. As shown in 
Figure 2-1 growth plate closure is shown as the “tidemark”, below which the 
calcified zone exists. The calcified zone serves as an important buffer between the 
non-calcified cartilage and the subchondral bone. These different layers have been 
thought to arise as a consequence of their adaptation to different mechanical and 
structural needs.  
 Chondrocytes maintain active membrane transport for the exchange of cations, 
including Na+, K+, Ca2+ and H+, whose intracellular concentrations fluctuate with 
load and composition changes of the cartilage matrix. Chondrocytes adapt to low 
oxygen tension by expressing angiogenic factors like VEGF [46]. They also express 
a number of a genes associated with anabolism and chondrocyte differentiation [19]. 
In contrast to the differentiating chondrocytes, ACCs  also express SMAD1, 
preventing progression towards endochondral ossification [50]. Several other factors 
important for chondrogenesis also play critical roles in articular cartilage 
homeostasis, particularly in supporting matrix metabolism. Of these, TGF-β and 
BMPs have been the most widely investigated [19].  
 The WNT signalling pathway has also been implicated in regulating 
chondrogenesis and hypertrophic maturation of chondrocytes [51, 52] . Chondrocytes  
are capable of responding to mechanical forces and structural changes in the 
surrounding cartilage matrix, as well as intrinsic and extrinsic growth factors, 
cytokines and other inflammatory mediators [34]. All these factors regulate discrete 
steps in chondrogenesis, in a synchronised manner, to maintain cartilage structure 
and homeostasis.  
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Figure 2-1 The structure of human adult articular cartilage 
 
This figure shows the zones of cellular distribution and the superficial, middle, and deep regions of 
matrix organization. It also shows the relative diameters and orientations of collagen fibrils in the 
different zones. The positions of the tidemark and subchondral bone also are noted. (Adapted from 
[53]). 
 
2.3.2 Osteoarthritis articular cartilage 
  Articular cartilage has remarkable durability. However, this tissue can be 
damaged by trauma or inflammatory processes that may cause a multitude of skeletal 
malformation syndromes as well as degradative diseases such as OA. In the early 
stages, OA typically manifests as fibrillations of the articular cartilage surface, and 
progressively degenerates the tissue at greater depths from the surface [54]. Early 
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indications of OA in the superficial zone include a reduction in the proteoglycans 
content and a transition in the collagen orientation from parallel to the bone surface 
to become randomly orientated [55]. In advanced cases, the articular cartilage may 
be completely worn out, exposing the subchondral bone. The molecular composition 
and organisation of arthritic articular cartilage  (shown in Figure 2-1), leading to a 
deterioration in the material properties and structural integrity of the articular surface 
and underlying hyaline cartilage. In OA of the knee, the medial compartment is more 
commonly affected than the lateral compartment. This is thought to be because  the 
medial compartment is more susceptible to weight bearing loads compared to the 
lateral compartment [56, 57]. This phenomenon is directly associated with cartilage 
damage and degradation as can be seen in Figure 2-2. 
Given chondrocytes are the unique cellular component of adult articular 
cartilage; scientists have typically focused on the role of chondrocytes in the 
pathogenesis of these alterations. These cells are capable of responding to 
mechanical forces and structural changes in the surrounding cartilage matrix, as well 
as intrinsic and extrinsic growth factors, cytokines and other inflammatory mediators 
[34].  A characteristic feature of chondrocytes in the progression of OA is clustering. 
This is the result of increased cell proliferation and general upregulation of synthetic 
activity associated with an increased production of specific ECM proteins. 
Chondrocytes also express certain terminal differentiation markers (COL10, ALP, 
OPN) suggesting that OA chondrocytes are differentiating towards an hypertropic 
phenotype or matured phenotypic state [58, 59]. Further, the production of COL1 and 
COL2 suggests the dedifferentiation process of chondrocytes [60]. This leads to the 
production of degradative proteinase genes like MMPs and ADAMs. These changes 
lead to gradual loss of proteoglycans followed by ECM degradation. Extensive 
cellular changes are also accompanied by increased expression of regulatory 
proteins.  These cellular changes are accompanied by fibrillation of the cartilage 
surface and localised production of fibrocartilage [61]. There are a number of genes 
reported to be associated with the degradation of cartilage in the progression of OA. 
Various studies have also shown the activation of the WNT signalling and MAPK 
pathways in OA patients and in OA animal models [62, 63]. There is also a 
continued debate as to whether BMP genes are up or down regulated in the 
progression of OA [19, 46]. 
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Figure 2-2 Healthy and osteoarthritic tibial plateau 
 
Translucent, white, healthy cartilage (left panel). Degraded cartilage (right panel), more degradation is 
observed in the medial compartment. From Jeon et al. 2010, [64]. 
2.4 BONE 
An adult human skeleton contains 206 bones. Bone is a highly organised and a 
dynamic tissue. The functions of bone are to provide mechanical support for soft 
tissues; act as levers for muscle action; protect the central nervous system. Bone also 
releases calcium and other ions for the maintenance of a constant ionic environment 
in the extracellular fluid, and support haematopoiesis.  There are two types of bone at 
the microscopic level, woven bone and lamellar bone. Woven bone is also known as 
immature bone, young bone or osteoid bone. It is found in the embryo, new born and 
growth plate in adults. Similar types of woven bone are also found in pathological 
conditions such as osteogenesis imperfecta and Paget disease. Woven bone has more 
cells per unit area and its mineral content varies. It is cross-fibered and contains no 
uniform orientation of collagen fibers. Research shows that the mechanical behaviour 
of this bone is the same regardless of its orientation of applied force [65, 66]. 
 Lamellar bone is mature bone and its collagen fibers are highly organised to 
withstand strain and stress and to give it anisotropic properties. The mechanical 
properties of lamellar bone depend and differ on the orientation of force applied, 
with its greatest strength parallel to the longitudinal axis of the collagen fibers. 
Lamellar bone is structurally organised into trabecular bone (spongy or cancellous) 
and cortical bone (dense or compact), based on the porosity and unit microstructure 
of the bone. The bone tissue consists of concentrical (compact bones) or parallel 
(spongy bones) organised lamellae of collagen fibers. In compact bones, the 
concentrically arranged lamellae surround a central channel that contains blood 
vessels and nerve fibres (Haversian canal). Perpendicular to this system runs the 
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Volkmann’s canals that provide inter-connections between the inner and outer layers 
of the bone. The organisation of bone is shown in Figure 2-3. At the molecular level, 
bone forms a perfect modulation of arranged apatite crystal arrangement and at the 
organ level, it has a trabecular network to withstand strain. Bone is composed of an 
organic and inorganic phase. The principle component of the organic phase is 
Collagen 1 (COL1). Collagen is laid in a complex pattern to provide strength to 
bones. The other components of bone are listed in table Table 2-1. Over the past two 
decades, research has lead to a greater understanding of the production of the ECM at 
the cellular level. ECM consists of mineral, collagen, water, non-collagenous 
proteins and lipids[66, 67]. 
Bone undergoes continuous destruction, called resorption, and formation by 
the three cells of the bone: osteoclasts, osteoblasts and osteocytes. In the adult 
skeleton, bone formation and bone resorption (known as bone remodelling) are in 
balance, maintaining a constant homeostatically controlled amount of bone.   
 
Figure 2-3 Organisation of bone 
 
 1. periosteum,  2. medullary canal containing marrow, 3. compact bone, 4. cancellous bone, 5. 
Haversian system, 6. osteocyte, 7. Haversian canal, 8.Volkmann’s canal, 9.Osteocyte, 10. Cannaculi 
11. Lacunae . (Adapted from the source: http://www.merriam-webster.com/art/med/bone.htm) 
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Table 2-1 Major components of human bone and their overall description 
(Adapted from [68]) 
 
Bone 
components 
Sub components description 
Inorganic 
phase 
HA= 
Ca  (PO ) (OH) 
10          4 6            2 
50% of bone, rigidity, salt and calcium storage
Organic 
phase 
Col I Serves as nucleation sites for the deposition of mineral components 
(HA), responsible for tensile strength (85%-90%) 
 Growth factors IGF, TGFβ, FGF, PDGF, HGF
 Glycosaminoglycans Chondroitin sulphate, dermatan sulphate, keratin sulphate, hyaluronic acid 
(located pericellular osteocytes) 
 OPN Synthesised by pre-osteoblasts, osteoblasts, osteocytes, bone marrow cells, 
high affinity to calcium, binding sites for integrin receptors throughout an 
RGD motif, important protein for matrix-cell-interaction, attachment of 
osteoclasts & cancer cells 
 ON Secreted by osteoblasts, binding collagen & calcium, initiating 
mineralisation, promoting mineral crystal formation, increases 
production & activity of MMPs 
Functions of ON beneficial to tumour cells: angiogenesis, proliferation, 
migration 
 OC Secreted by osteoblasts, mineralisation & calcium homeostasis, bone gla- 
protein, mineral–binding ECM protein 
 BSP 8% of non-collagenous ECM, maybe nucleus for the formation of the 
first apatite crystals, inhibit crystal growth & MMP2 activation and 
angiogenesis, regulation of tumour growth in bone, cell attachment 
protein, enhances osteoblast differentiation & mineralisation 
Cells Osteoblasts Located on the surface of an osteoid seam, producing a protein mix 
called osteoid high activity of alkaline phosphatase, responsible for 
matrix mineralisation 
 Osteocytes 90% of bone cells. Originated from osteoblasts, become trapped & 
embedded in the matrix they produce themselves, space they occupy is 
known as lacunae. Orchestrates bone remodelling, matrix maintenance, 
calcium homeostasis, mechano-sensory receptors (regulation of the bone’s 
response to stress and mechanical load) 
 Osteoclasts Responsible for bone resorption, large multinucleated cells on the 
bone surface forming resorption pits, so called Howship lacunae, bone 
resorption through enzymes such as the tartrate resistant phosphatase 
(TRAP) 
 
 
2.4.1 Bone Development and growth 
Bone formation begins during prenatal development and continues 
throughout adulthood. Osteogenesis or bone formation occurs through two processes. 
(1) Intramembranous ossification: the process by which flat bones are formed, 
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involving the replacement of connective tissue membrane sheets with bone tissue 
occurring without a cartilage template. (2) Endochondral ossification: this process 
involves the replacement of the avascular cartilage template with bone tissue (e.g- 
femur, tibia). It is an essential process during the rudimentary formation of long 
bones This takes place in the growth plate, a specialised cartilaginous structure 
located in the area between epiphysis and the diaphysis of infants and adolescents 
[69]. 
2.4.2 Bone Modelling 
Modelling is a process where bone formation and bone resorption occurs on 
separate surfaces and is not coupled. It is through this process that skeletal mass and 
structure is defined during birth to adulthood [65]. 
2.4.3 Bone Remodelling 
Bone is a dynamic tissue and is continually renewed. Bone cells that are 
derived from different progenitor pools are under distinct molecular control 
mechanisms. Bone cells form temporary anatomical structures called basic 
multicellular units (BMU) that execute bone formation and bone remodelling. This is 
essential in maintaining bone homeostasis / bone mass and skeletal micro-
architecture . This process involves the coupling of bone formation and bone 
resorption [65].  Bone remodelling involves 5 stages and they are explained in Table 
2-2 and Figure 2-4. 
 
Table 2-2  Five stages of bone remodelling 
(Adapted from [68, 70]) 
 
 
 
 
 
 
 
 
 
 
Five stages Stage description 
Activation Preosteoclasts are stimulated and differentiate under 
the influence of cytokines and growth factors into 
mature active osteoclasts 
Resorption Osteoclasts digest mineral matrix (old bone) 
Reversal Formation of cement line. End of resorption  
Formation Osteoblasts synthesize new bone matrix 
Quiescence Osteoblasts become resting bone lining cells on the 
newly formed bone surface 
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Figure 2-4 Stages of bone remodelling 
1. Resting state; 2. Resorption; 3.Reversal; 4.Formation; 5. Mineralisation; 6.Resting state 
2.5 OSTEOCYTES 
Microscopically, bone has three characteristic cell types: osteoblasts, 
osteocytes, and osteoclasts. The overall functions of these are listed in Table 2-1. 
The core focus area of this thesis is upon osteocytes which constitute over 90% of the 
bone cells that are embedded in the bone matrix. 
2.5.1 Introduction 
The main cellular component of the mammalian bone is the osteocyte.  
Osteocytes represent more than 90% of all the bone cells (20,000 to 80,000 
cells/mm3 of bone tissue). There are approximately 20-fold more osteocytes than 
osteoblasts in bone [71, 72]. Osteocyte density has been evaluated at 31,900 and 
93,200 cells/mm3 in bovine and murine bone respectively [73]. In human bone, the 
average half life of osteocytes is postulated to be 25 years [74]. However as bone 
remodeling is of 4% to 10% per year [75], the expected duration of the life of an 
osteocyte is difficult to determine and is unlikely to be this long. The life duration of 
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osteocytes is higher than that of osteoblasts, which is an estimated 3 months in 
human bone [75] and 10– 20 days in murine woven bone [76]. 
2.5.2 Osteocyte size 
The size of osteocytes varies between species [73]. The relative size of the 
lacunae and canalliculi dictate the degree of fluid flow and the maximum size of 
particles that might migrate through the system extracellularly. The dimensions of 
murine osteocyte lacuna is in the range of 5μm by 20μm  [74] with a gap present 
between the cell and the lacuna wall. Similarly, the cytoplasmic processes are 
approximately half the diameter of the canalliculi (canalliculi range between 50nm 
and 100 nm in diameter) [74] leaving a gap sufficient for two processes to lie side by 
side at points of gap junctional communication. In humans, osteocytes are 
approximately 9μm in the short axis by 20μm in the long axis [77]. It has been noted, 
that a mesh of extracellular material, primarily proteoglycans, are present in at least 
some volumes of canaliculi and might assist in the amplification of fluid flow driven 
mechanical signals [75]. The exact location of the mechanosensor in these cells is 
still to be determined but the presence of a primary (non-motile) cilium on osteocytes 
has been reported and they are known to sense mechanical stimuli in other cell types 
[76]. 
2.5.3 Osteocyte morphology 
Osteocytes have a very unique dendritic morphology, while their cell body 
has a fusiform shape in long bones or a rounded shape in flat bones [77]. Osteocytes 
are localised in an osteocytic lacuna and are buried in the matrix [15]. The dendrites 
extend into channels in the matrix, these channels are called canalliculi. Osteocytes 
communicate with each other and with the cells at the surface of the bone tissue via 
these dendrites (Figure 2-5). Recent research shows that osteocytes could 
communicate  through gap junctions  [78]. The lacuno-canalicular system constitutes 
a molecular exchange surface area. The extracellular fluid in the lacunar-canalicular 
space is believed to be able to stimulate osteocytes by mechanical loading-induced 
fluid flow shear stress [79]. Their special morphology implies multiple potential 
roles such as mechanosensors and communicators. Thus, bone cells form a functional 
network (well organised in cortical bone and disorganised in woven or immature 
bone) within which, cells at all stages of bone formation from preosteoblast to 
mature osteocytes remain connected. It is considered that the morphology of 
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osteocytes alter in various disease processes [80, 81]. However, these changes have 
still not been visualised nor quantified adequately [80]. 
 
 
Figure 2-5 Morphology of an osteocyte 
 
The Scanning Electron Microscopy image shows an osteocyte and its structure from an acid etched 
human tibial bone surface – Coloured using Adobe Photoshop. 
 
2.5.4 Molecular markers/ drivers of osteocytes 
It is well accepted that osteocytes are derived from osteoblasts [71, 82]. Osteocyte 
specific proteins are expressed when osteoblasts stop actively producing the bone 
matrix and become embedded in their own osteoid where they differentiate into 
osteocytes [79]. Functional studies have been conducted recently on a few osteocyte 
specific proteins. With results indicating that E11/gp38 (Podoplanin) is expressed 
most highly in the newly embedded osteocytes [83, 84]. It is inferred that E11/gp38 
may be important for osteocyte dendrite formation since it is also expressed on other 
dendritic cells. E11 is also known to be highly expressed in woven/young bone 
compared to mature bone.  The functions of DMP1(Dentin Matrix Protein 1), PHEX 
(Phosphate Regulating Endopeptidase Homolog, X-linked) and MEPE (Matrix 
Extracellular Phosphoglycoprotein) are related to phosphate homeostasis and mineral 
metabolism [85, 86]. SOST (Sclerostin) is expressed by mature osteocytes and 
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functions as an osteoblast inhibitor/negative regulator of bone formation/WNT 
inhibitor [87].  
Based on a few functional studies and morphological observations, osteocyte 
specific proteins are expressed when osteoblasts differentiate into osteocytes as 
depicted in Figure 2-6. 
 
 
 
Figure 2-6 Differentiation of osteoblast to osteocyte and proteins expressed at specific stage of 
differentiation 
 
Osteocyte proteins and their associated functions are listed in Table 2-3. 
Various signalling pathways like WNT and TGFβ have been implicated in the tight 
regulation of osteocytes to maintain bone homeostasis. However, the mechanisms 
and implications are still unclear [14]. 
 
Table 2-3 Osteocyte specific proteins, stage of expression in differentiation and their potential 
function 
 
Protein Expression Potential function 
E11/gp38 
Immature osteocytes/newly 
embedded     
 Dendrite formation 
PHEX, MEPE Immature and mature osteocytes                
Phosphate homeostasis 
DMP1 
Immature and mature 
osteocytes                
Phosphate homeostasis and 
regulator of bone 
mineralisation 
SOST 
Mature osteocytes/deeply 
embedded         
Osteoblast  
inhibitor/Inhibitor of bone 
formation 
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2.5.5 Functional role of osteocytes 
Control of bone formation and bone resorption 
Discoveries in recent years have confirmed the idea of osteocytes from being 
passive metabolically inactive cells to endocrine cells and orchestrators of bone 
remodelling. Research suggests that osteocytes are related to bone resorbing 
osteoclasts, can resorb mineralized bone matrix and also play a vital role in 
regulating bone formation. Osteocytes are now known and scientifically confirmed to 
be the orchestrators of bone (re)modelling, this having been a concept in existence 
for sometime [88]. The overall functions have been tabulated in Table 2-4.  
Function of osteocytes in  regulating bone resorption 
Bone resorption has different functions that include, removal of calcified 
cartilage during bone growth, maintaing mineral metabolism, and assisting in bone 
modeling during growth or adaptation. Osteoclasts are relatively short lived and they 
are generated continuously at sites of bone resorption. The idea that osteocytes play a 
role in bone remodelling has existed for many decades and was suggested 
approximately 100 years ago [89].  However, it was only recently in 2007 that the 
osteocyte functional evidence was provided by Tatsumi et al [90]. Various other 
researchers have since added to this knowledge using transgenic mice [91] . 
Osteocytes express RANKL and when RANKL is deleted in mice osteocytes, they 
have increased bone mass. These results demonstrate that RANKL is expressed 10-
fold more in osteocytes compared to osteoblasts and are better promoters/supporters 
of bone formation [92]. Experiments conducted by Wysolmerski et al shows 
lactation induces osteocytic lacunar and canalicular enlargement that returns to virgin 
levels post lactation [89, 93, 94]. We can then infer that osteocyte perilacunar matrix 
acts a source of calcium in a calcium demanding condition. In this study, the width, 
lacunar size and lacunar area were significantly increased in the trabacular bone of 
the lactating mice. Further, gene expression data revealed that osteocytes expressed 
cathapsin K and showed TRAP activity necessary for bone resorption. Therefore 
osteocytes use some of the mechanisms used by osteoclasts to remove bone matrix 
and osteocyte perilacunar matrix [93] .  
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Function of osteocytes in  regulating bone formation 
The discovery of sclerostin (WNT inhibitor) in 2001 as a product of 
osteocytes provided the first functional evidence that osteocytes could control the 
differentiation and activity of osteoblasts and also play a role in bone formation [95, 
96]. Further to Wysolmerski’s experiments as explained; post weening, the osteocyte 
perilacunar membrane returns to its normal form suggesting that osteocytes replace 
the perilacunar membrane [89, 93]. Further evidence shows that isolated 
preosteocytes can partially dedifferentiate into matrix producing osteoblasts and 
express genes required for bone formation [97]. This suggests that osteocytes can act 
as a source of matrix bone forming osteoblasts.  
Together, osteocytes play a role in bone formation and mineralisation. As promoters 
of mineralisation they secrete proteins such as Dmp1 and Phex. As inhibitors of 
mineralisation and bone formation proteins such as SOST/sclerostin and 
MEPE/OF45) are highly expressed in osteocytes. These supporters and inhibitors of 
bone formation and mineralisation are most likely exquisitely balanced to maintain 
equilibrium and subsequently bone mass. Osteocytes also appear to play a major role 
in the regulation of osteoclasts by both inhibiting and activating osteoclastic 
resorption (expressing cathapsin K and TRAP). It has recently been shown that with 
loading, the osteocytes send signals inhibiting osteoclast activation. In contrast, 
compromised, hypoxic, apoptotic or dying osteocytes (especially with unloading), 
appear to send unknown signals to osteoclasts/preosteoclasts on the bone surface to 
initiate resorption. Therefore, osteocytes within the bone regulate bone formation and 
mineralisation and inhibit osteoclastic resorption. These have the capacity to also 
send signals of osteoclast activation under specific conditions like microgravity 
which is associated with space lift [98], restricted calcium intake [99, 100] and 
animals undergoing hibernation [101]. 
Osteocyte: Control through death 
Osteocytes are cells that not only play a physiological role during their life 
time, but also achieve functions through their apoptosis, necrosis and autophagy. It 
has been known for a very long time that osteocytes die before the matrix is 
resorbed. Modelling is a process by which bone expands and is reconstructed to 
achieve the requirements of growth. Osteocytes are known to trigger signals 
transmitted through the canalicular network to osteoclasts or osteoblasts [15], 
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resulting in bone loss or gain as needed, whereas physiological strain maintains bone 
mass [102]. Remodelling is the process that begins with osteoclastic resorption, by 
which bone tissue is removed and replaced [103]. A mechanism by which osteocytes 
may trigger bone resorption is by undergoing premature apoptosis [104].  Osteocyte 
apoptosis may also contribute to bone strength by mechanisms independent of the 
amount of mineral [105]. Evidence has shown that there is a strong relationship 
between osteocyte death and bone remodelling capability [90]. Previous studies have 
shown that osteocyte apoptosis is associated with bone formation and bone loss 
[105]. Hence, knowing the role of osteocytes in targeting bone destruction through 
apoptosis, it is important to know and understand the changes with apoptosis in 
various bone diseases. 
 
Table 2-4 Functions of osteocytes 
Tabulated from comprehensive review The Osteocyte: An Endocrine Cell and More (Sarah L. Dallas , 
PhD, Matthew Prideaux, PhD and Lynda F. Bonewald, PhD)  [14] 
 
 
 Osteoid osteocytes control mineralization through PHEX/Dmp1 
 Play a role in calcium homeostasis in response to PTH 
 Can recruit osteoclasts through expression of RANKL with or without cell death.  
 Osteocytes express  Cathepsin  K and play a role in osteocytic osteolysis. 
Professor Lynda Bonewald shows that osteocytes can create an acidic 
microenvironment in response to PTH (long term and rapid effect) using proton 
pump in an IDGT cell line (unpublished data, from her presentation at IBMS-
JSBMR 2013, Kobe, Japan) 
 They can regulate osteoblast activity through sclerostin, MEPE, PGE2 
 Osteocytes are  mechanosensory  cells through WNT β-catenin signalling 
 Produce FGF23 to target the kidney and regulate phosphate homeostasis. FGF23 
is elevated in osteocytes in chronic kidney diseases and associated with cardiac 
hypertrophy 
 They are regulators of muscle myogenesis and function 
 Osteocytes regulate myelopoiesis haematopoiesis through  a process involving 
G-CSF  
 Under calcium restriction, osteocytes remove calcium from bone through a 
process involving the vitamin D receptor  
 Osteocytes can remove perilacunar matrix upon calcium demand during lactation 
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2.5.6 In vitro models of osteocyte 
In contrast to osteoblast and osteoclasts, osteocytes have functions that are largely 
unknown.  Research into osteocyte function is restricted due to; the lack of suitable 
cell lines; reduced availability of osteocyte-specific promoters for targeted transgenic 
approaches; and it is difficult to maintain their differentiated function in vitro. 
Bonewald and co-workers established a cell line with features ascribed to osteocytes. 
This cell is named Murine Long Bone Osteocyte Y4 (MLO-Y4) to emphasise the 
fact that it was established from long bones that respond to increased mechanical 
stress with an increase in bone formation. ML0-Y4 is an immortalised bone cell of 
the osteocyte phenotype derived from transgenic mice that over expressing SV40 
large T-antigen oncogene driven by the osteocalcin promoter. This cell line was 
characterised and its properties compared with the known properties of osteocytes, 
osteoblasts and other cells [106]. MLO-Y4 is accepted as an established primary 
osteocyte cell line. When seeded at low density, they display complex dendritic 
processes. Their biochemical profile includes high amounts of E11/gp38/podoplanin, 
CD44, osteocalcin, and osteopontin, but low levels of alkaline phosphatase (ALP) 
activity. Functionally, these cells support osteoclast formation and activation in the 
absence of any osteotropic factors [107]. In the presence of estrogens, their ability to 
support osteoclast formation is decreased via an increase in TGFβ3 [108]. MLO-Y4 
cells have also been found to support osteoblast mesenchymal stem cell 
differentiation [109], supporting the hypothesis that osteocytes are orchestrators of 
bone resorption and bone formation. (ML0-Y4 cells and cell culture protocols has 
been kindly provided by Dr. Lynda F. Bonewald, University of Missouri-Kansas 
City, Kansas City, MO, USA) for use in this study.) In the last few years a number of 
other cell lines have been reported and their phenotypic characteristics are tabulated 
in Table 2-5 [110]. 
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Table 2-5 In vitro models of osteocyte and their phenotypic characteristics  
(Adapted from [110]) 
 
 
Cell Line, 
Year 
established 
& reference 
 
Source 
 
Method of 
immortalization 
 
Proliferation 
 
Gene Expression 
 
MLO-Y4, 
1997 
 
14 d.o mouse 
long bone 
 
Cells derived from 
a mouse expressing 
the SV40 T antigen 
under the control 
of an osteocalcin 
promoter  
 
Yes 
 
ALP, OC, E11, CX43, 
DMP1,FGF23 
 
MLO-A5, 
2001 
 
14 d.o mouse 
long bone 
 
Cells derived from 
a mouse expressing 
the SV40 T antigen 
under the control 
of an osteocalcin 
promoter  
 
Yes 
 
 
ALP, OC, E11, CX43, DMP1, 
SOST, FGF23 
 
HOB-01-C1, 
1996 
 
Human 
trabecular 
bone 
 
Thermolabile 
SV40 T antigen 
construct, active at 
34 °C, inactive at 
39–40 °C allowing 
conditional 
immortalisation 
 
No 
 (37–40 °C) 
 
ALP,OC 
 
OC1/14/59, 
2001 
 
E18.5 mouse 
calvaria, 
PTH1R −/− 
 
Mice have an 
IFNγ-inducible 
promoter driving 
thermolabile SV40 
T antigen 
expression 
allowing 
conditional 
immortalisation 
 
No 
(37–40 °C) 
 
ALP,OC,CX43 
 
IDG-SW3, 
2011 
 
mouse long 
bone, Dmp-
GFP + 
 
Expression 
low/absent initially 
but present after 1–
2 weeks in 
differentiation 
conditions 
 
No 
(37–40 °C) 
 
ALP,E11,DMP1,SOST,FGF23 
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2.6 OSTEOARTHRITIS SUBCHONDRAL BONE 
2.6.1 Structure and function of subchondral bone 
The periarticular bone can be separated into two distinct anatomic structures; 
the subchondral plate at the joint margins and the subchondral trabacular bone that 
exists below the calcified layer of the mature articular cartilage. The subchondral 
bone plate consists of a cortical bone plate that is relatively non-porous and poorly 
vascularised as shown in Figure 2-7. Although the differences between the two 
distinct anatomic structures are unclear, these two tissues are organised differently to 
adapt to mechanical loading [111, 112]. One of the main roles of the subchondral 
bone is to provide support to the overlying articular cartilage [113]. Its unique 
architecture allows it to adapt to mechanical stress [114] and absorb mechanical 
force transmitted through the joint [1, 113] while playing catabolic and anabolic roles 
in cartilage metabolism and joint homeostasis. 
  
 
Figure 2-7  Different zones of cartilage and subchondral bone 
  
Safronin-O-staining showing different zones of cartilage and subchondral bone (Left panel). A 
scanning electron micrograph of subchondral bone (right panel), from a 75-yr-old patient suffering 
with OA, showing a porous and dense texture of the bone matrix. (Scale bar 100 μm) (Image from 
[115]). 
2.6.2 Knee osteoarthritis 
The knee is the weight bearing joint most commonly affected by OA. Each 
knee has three ‘compartments’ where OA can occur; the inner (medial) or outer 
(lateral) side of the joint between the thighbone (femur) and shinbone (tibia), or 
between the kneecap (patella) and the thighbone. All compartments or a combination 
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of compartments in either or both knees may be affected [116]. In OA of the knee, 
the medial compartment is more commonly affected than the lateral compartment. 
Knee OA is commonly defined by structural pathology, such as on a radiograph, and 
clinically using joint symptoms [7, 34].  
The research conducted in this thesis focuses on knee OA and specifically the 
lateral and medial compartment of the tibial plateau obtained after knee replacement 
surgeries, unless stated otherwise.   
2.6.3 Subchondral bone changes in osteoarthritis 
 The classical view for the pathogenesis of OA is the degeneration of articular 
cartilage associated with subchondral bone changes. The predominant typical feature 
of OA is characterised by joint space narrowing, advancement of tidemark, cartilage 
fibrillation, progressive subchondral bone thickness, osteophyte formation and 
development of subchondral cysts and lesions as shown in Figure 2-8. 
 For several decades, research has focused on the mechanisms involved in the 
destruction of articular cartilage. Over, 30 years ago, Radin and Rose postulated that 
the integrity of subchondral bone is directly related to the cartilage integrity although 
only recently research re-emphasised the importance of subchondral bone changes 
like structure, architecture, quality (sclerosis) and regulation as an important 
distinguishing feature of OA [1]. Studies in humans show that the changes in bone 
occur very early in OA. Studies in hand OA with isotope-labelled bone-seeking 
agents found that bone turnover preceded bony changes [117, 118]. Another study, 
conducted over 5 years on patients suffering with knee OA showed that elevated 
subchondral bone cell activity in the baseline case predicted subsequent loss of joint 
space on radiographs [119]. Although human studies typically focus on late or end 
stage disease and reveal less about the progression of the disease, many animal and 
in vitro studies (focussing on osteoblast and osteoclast) also support the concept of 
bone changes to precede cartilage degradation. Having said this, some animal models 
demonstrate conflicting results. For example: shock-load experiments in rabbits 
found that changes in the mechanical properties of subchondral bone and cartilage 
degeneration occurred simultaneously [120].  
  Another important factor is the biochemical and mineral composition of OA 
subchondral bone tissue. The majority of studies (in vitro and in vivo) indicate, that 
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in OA, there is more subchondral bone thickness, and a view that is largely agreed 
upon in this field [10, 21]. However, some arguments exist about the bone being 
hypo or hyper-mineralised. Mineralisation is both a biological and physiochemical 
process. Reports show that there is an increased bone mineral density with 
progression of OA and an inverse relationship between osteoporosis and OA [121-
123]. This being said, other studies show an abnormally low bone mineralisation 
[124] like in osteoporosis. In ideal physiological conditions, in an adult skeleton, the 
bone remodelling process is perfectly balanced to provide a mechanism for repairing 
damage that occurs during mechanical loading and stress [111, 125]. However in 
OA, irrespective of whether bone changes precede cartilage breakdown or not, or 
whether the bone is hyper or hypo mineralised, it can be definitely said the 
remodelling balance is hampered and the mechanisms involved in these progressive 
changes are unclear. Several signalling proteins and pathways are known to be 
imperative in the regulation of bone remodelling. The interplay and cross-talk 
between cell signalling pathways like TGF-β, BMP, WNT, and NOTCH have been 
implicated in OA. All these studies have been conducted on osteoblasts and 
osteoclasts and the associated characteristic effects of signalling pathways on 
osteoblast and osteoclast. However, the direct mechanisms involved are unclear and 
therapeutic interventions are far from being used. Some authors have hypothesised 
that vascular disturbance could cause necrosis in the subchondral bone and may be 
involved in the abnormal bone remodelling [126]. More recently some authors 
hypothesise that role of low-dose cytokine expression and osteocyte apoptosis are 
associated with disrupted bone remodelling in OA [127]. However, all these are 
perspectives and lack evidence and functional studies. 
In summary, the exact sequence of OA progression is still under debate and 
unclear. Literature reveals that hampered bone remodelling exists (with net bone 
formation and hampered bone mineral metabolism)[128]. Significant amount of 
research has been conducted on osteoblasts and osteoclasts and it is well known that 
they undergo changes in OA. Osteocytes, as mentioned previously, have been 
studied only in the past decade with findings indicateing that osteocytes are central to 
bone homeostasis.  
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Figure 2-8  Pathogenic features in a normal and osteoarthritic knee joint 
 
Normal Healthy tissue of lateral compartment is shown: normal cartilage without any fissures and no 
signs of synovial inflammation. Osteoarthritis: Early focal degenerate lesion and fibrillated cartilage, 
as well as remodelling of bone, is observed in medial compartment in OA patients. Bony outgrowth 
(osteophyte) and subchondral sclerosis are also noted. 
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2.7 INFLAMMATION AND OSTEOARTHRITIS 
Inflammation is a protective pattern of response controlling tissue damage 
occurring as a result of pathogenic, traumatic or toxic injury. The inflammatory 
process is governed by both pro and anti-inflammatory molecules which require 
distinct cell types and various factors that act (in a co-ordinated manner) to regulate 
cell chemotaxis, migration and proliferation leading to tissue repair [129].  
Under normal physiological conditions, inflammation is tightly regulated and 
modulated by the actions of soluble proteins (cytokines and growth factors) acting 
between inflammatory cells, fibroblasts and vascular ECs within the affected site 
[130]. When inflammation is not properly regulated the balance is shifted away from 
the initiation of the healing process towards the occurrence of persisting 
inflammation [131]. Thus, the initiation and the control of inflammation are crucial 
elements. Inflammation is increasingly thought to enhance structural severity in OA, 
whether it is through the biochemical changes within the cartilage and the release of 
the cartilage breakdown products in the synovial fluid [132] or the subchondral bone 
changes. Researchers have implicated T cells in producing pro-inflammatory 
cytokines and MMPs within the inflamed synovial membranes [133], as well as 
increased infiltration of mononuclear cell and an over expression of mediators of 
inflammation process in early OA [134]. Considerable amounts of evidence from in 
vitro and in vivo studies support the view that a link exists between: increased levels 
of catabolic enzymes; and inflammatory mediators in OA synovial fluid; and joint 
tissue [135, 136]. Mechanical forces in OA may also produce metabolic changes that 
result in cytokine production by the synovium [137]. A heightened number of 
migratory inflammatory cells and the substances secreted by these have been 
recognised in the osteoarthritic joint tissues. This is considered not nearly as much as 
in the case of rheumatoid arthritis, which is clearly an autoimmune disease. 
However, it is considered enough to raise the question if inflammation is also a major 
player in OA [138]. This view is strongly supported by Professor William Robinson 
from Stanford University School of Medicine, who believes that OA is largely driven 
by an inflammatory process [18].  
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2.7.1 Cytokines 
Biological activities mediated by cell-derived factors were suggested for the 
first time by Rich and Lews in 1932. When lymphocytes were exposed to antigens, 
the migration of normal macrophages was inhibited by macrophage migration 
inhibitory factors (MIFs). MIF’s generated during the interaction of sensitised 
lymphocytes with specific antigens was termed cytokines. Tumor necrosis factor 
(TNFα) was the first monocyte/macrophage derived cytokine that was originally 
identified as cytotoxic protein present in the serum of animals sensitised with 
Bacillus Calmette-Gurin [139]. Cytokines can be defined as regulatory proteins 
secreted by WBCs and a variety of other cells in the body and their actions include 
numerous effects on cells of the immune system and modulation of the inflammatory 
response [140]. Characteristic features (cell source, cell target and primary effects) of 
cytokines and key categories have been tabulated in Table 2-7. 
 It is important to remember that cytokines are produced by, and act on many 
different cells, making any attempt to categorise them subject to limitations.                                                      
Cytokines feature at the forefront of biomedical research [141]. An 
understanding of their properties is essential for any therapeutic/biological cure for 
disease or condition. Some reasons to be interested in cytokines have been tabulated 
in Table 2-6. 
For the purpose of this study and thesis, further discussion will follow about 
Tumor necrosis factor family, specifically Tumor necrosis factor α (TNFα). 
Table 2-6 Why should we be interested in cytokines?[141] 
 
Important consideration of cytokines include: 
 Recombinant cytokines provide useful laboratory probes for studying different mechanisms 
 Orchestrators of host defence mechanism involved in response to exogenous and 
endogenous insults, repair and restoration of homeostasis 
 Believed to play a role in embryonic inductive factors 
 Maintain our capacity for daily survival in our germ-laden environment 
 The study of cytokine is unique and interdisciplinary 
 They act over short distances as autocrine or paracrine intercellular signals in local tissues 
and only occasionally spill over into the circulation and initiate systemic reactions. 
 Cytokines are short lived 
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Table 2-7 Characteristic features and categories of cytokines[140] 
 
 
 
1) Mediators of natural immunity 
Cytokine Cell source Cell target Primary effects 
TNFα (Type I 
Interferon) 
Macrophages; T cells 
T cells; B cells 
Endothelial cells 
Hypothalamus 
Liver 
Costimulatory molecule 
Activation 
(inflammation) 
Fever 
Acute phase reactants 
IL-1 
Monocytes  
Macrophages 
Fibroblasts 
Epithelial cells 
Endothelial cells 
Astrocytes 
T cells; B cells 
Endothelial cells 
Hypothalamus 
Liver 
Costimulatory molecule 
Activation 
(inflammation) 
Fever 
Acute phase reactants 
IL-10 T cells (TH2) 
Macrophages 
T cells 
Inhibits APC activity 
Inhibits cytokine 
production 
IL-12 Macrophages; NK cells Naive T cells 
Differentiation into a 
TH 1 cell 
TNF-gamma T cells; NK cells 
Monocytes 
Endothelial cells 
Many tissue cells -
  especially macrophages 
Activation 
Activation 
Increased class I and II 
MHC 
Chemokines leukocyte  
recruit leukocytes 
lymphocyte trafficking. 
2) Mediators of adaptive immunity 
IL-2 T cells; NK cells 
T cells 
B cells 
Monocytes 
Growth 
Growth 
Activation 
IL-4 T cells 
Naive T cells 
T cells 
B cells 
Differentiation into a 
TH 2 cell 
Growth 
Activation and growth; 
Isotype switching to IgE 
IL-5 T cells B cells 
Eosinophils 
Growth and activation 
TGF-β T cells; Macrophages T cells 
Macrophages 
Inhibits activation and 
growth 
Inhibits activation 
3) Stimulators of haematopoiesis 
GM-CSF 
T cells; Macrophages; 
Endothelial cells, 
Fibroblasts 
Bone marrow 
progenitors 
Growth and 
differentiation 
MCSF  
monocytes and 
macrophages 
growth and 
differentiation  
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2.7.2 TNFa- Structure and Response 
TNFα (also known as cachectin) belongs to the Tumor Necrosis Factor (TNF)  
superfamily of cytokines representing a multifunctional group of pro-inflammatory 
cytokines which activate signalling pathways for cell survival, apoptosis, 
inflammatory responses, and cellular differentiation. It is a 17 kDa protein that is 
produced by macrophages and other cells. The main sources in vivo are stimulated 
monocytes, fibroblasts, and endothelial cells, while additional producers of TNFα 
after stimulation are: macrophages, T-cells and B-lymphocytes, granulocytes, smooth 
muscle cells, eosinophils, chondrocytes, osteoblasts, mast cells, glial cells, and 
keratinocytes. Glioblastoma cells constitutively produce TNFα and the factor can be 
detected also in the cerebrospinal fluid. Human milk also contains TNFα [142]. 
The gene for human TNFα is located on chromosome 6 (murine chromosome 
17). It has a length of approximately 5 kb and contains four exons and three introns. 
Interestingly, more than 80% of the mature TNFα sequence is encoded in the fourth 
exon. The nucleotide sequences of TNFα and G-CSF genes resemble each other in a 
way that suggests a possible evolutionary relationship [143, 144]. 
TNFR1/p55/p60 (molecular mass: 55-60kDa) and TNFR2/p75/p80 (molecular 
mass: 75-80kDa) are the two forms of transmembrane TNFα receptors. Both these 
receptors differ in their affinity and are believed to be present on virtually all cell 
types except for the red blood cells [145]. TNFα binds to its receptors with high 
affinity however there are some species specificity in terms of the receptor subtype 
and TNFα binding. Binding of TNFα to TNFR1 is considered to be an irreversible 
mechanism, whereas TNFα binding to TNFR2 is considered both rapid on and off 
kinetics. However less is known about the mechanisms of signal transduction and 
biological function of TNFR2 [143, 145-147]. 
2.7.3 Biological effects of TNFa 
TNFα is considered a key mediator of inflammation. Its biological effects are 
influenced by complex array of factors like the level of tissue exposure to free and 
unbound TNFα; interaction of TNFα with other cytokines; duration of exposure to 
TNFα, paracrine effects of TNFα produced locally in different tissues; and the 
development of tolerance. The biological effects of TNFα have been studied for 
decades and some of these activities have been summarised in Table 2-7.  
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TNFα has been implicated in a number of diseases including OA, RA, AIDS, 
Anaemia, Cachexia, Cerebral malaria, Diabetes mellitus, Disseminated intravascular 
coagulopathy, Hepatitis, Insulin resistance, Meningitis, Multiple sclerosis, Obesity, 
Rejection of implanted organs, Stroke and Tuberculosis [143, 148].  
2.8 WNT SIGNALLING PATHWAY 
2.8.1 General Information 
WNTs are a family of 19 cysteine–rich secreted glycoproteins that locally 
activate receptor-mediated signalling pathways. The WNT Signalling pathway and 
its functions in bone homeostasis are well documented. WNTs are associated with 
postnatal cartilage differentiation, cartilage matrix catabolism and inhibition of 
chondrocyte apoptosis. In addition, these are known to play an important role by 
controlling differentiation of bone forming osteoblasts and bone resorbing osteoclasts 
[149]. Although WNT proteins signal through several pathways, the canonical 
pathway appears to be particularly important for bone biology. This is due to its 
complexities and current understandings of critical aspects of skeletal biology that 
has been reviewed by many researchers [150, 151].  
2.8.2 WNT β-catenin (Canonical) Pathway 
This Pathway involves the interaction of WNT ligands with low-density 
lipoprotein receptor–related protein 5 or 6 (LRP 5 or 6) and the frizzled (FZD). 
When WNT’s bind to frizzled and LRP5/6 in a ternary complex, glycogen synthase 
kinase 3 (GSK-3β) is inhibited, leading to the accumulation of β-catenin. 
Accumulated β-catenin then translocates into the nucleus and activates the lymphoid 
enhancer factor (LEF)/ T-cell factor (TCF)-mediated gene transcription. In the 
absence of WNTs, GSK-3β phosphorylates β-catenin and this phosphorylated β-
catenin is conjugated with ubiquitin and degraded by proteosome. WNT signalling is 
modulated not only through fine tuning by a large number of WNT ligands and also 
by extracellular antagonists or WNT inhibitors like DKK1, SOST (which binds to 
LRP5/6) and sFRP. The WNT signalling is also activated by three other pathways, 
including the planar cell polarity pathway, the protein kinase pathway and the 
WNT/ca2+ pathway [152, 153] however, its mechanisms are currently not as well 
understood in skeletal development and disease.  
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A simplified view of the canonical pathway (active and inactivate) has been 
explained in Figure 2-9.  
 
 
Figure 2-9 Activated and inactivated state of WNT signalling pathway 
Adapted from [154]  
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2.8.3 WNT signalling pathway in joint homeostasis 
A critical step in skeletal morphogenesis is the formation of synovial joints 
which define the relative size of discrete skeletal elements and are required for the 
mobility of vertebrates. The WNT signalling cascades have essential roles in the 
development, growth and homeostasis of joints and the skeleton. The WNT β-catenin 
pathway has been associated with postnatal cartilage matrix catabolism [155], 
articular chondrocyte dedifferentiation and the inhibition of chondrocyte apoptosis 
[156, 157]. The majority of available data provides circumstantial and/or direct 
evidence (both in vivo and in vitro), that activation of WNT β-catenin signalling 
leads to reprogramming of articular chondrocytes towards catabolism or loss of 
stable phenotype with subsequent loss of tissue structure and function. During 
skeletal development, WNT’s have been implicated initially in proximal-distal 
outgrowth and dorsoventral limb patterning and later, in chondrogenesis, 
osteogenesis, myogenesis and adipogenesis [158, 159]. Mutant mice with reduced 
expression of LRP 5/6 resulted in defective limbs [160], whereas mouse embryos 
lacking in WNT co-receptors or β-catenin resulted in defective bone cartilage and 
joints. Mutations in co-receptors LRP 4 resulted in webbed toes through bone fusions 
[161, 162] and limb malformations in mice to have found with altered gene doses of 
SOST [163]. Skeletal malformations were also found in humans with mutation of 
WNT3a. WNT 4a and WNT 14 are required for joint formation and WNT5a 
mediated signalling is also essential for skeletal development. Therefore, WNT’s 
play a critical role in mesenchymal stem cell lineage commitment and progression, 
by indirectly repressing osteoclast (haematopoietic lineage) differentiation and bone 
resorption through the increased secretion of osteoprotegrin (OPG). The impact of 
WNT β-catenin signalling on bone cells is illustrated in Figure 2-10. Across all 
studies to WNT signalling pathway, increases in bone mass have been observed as a 
result of pathway activation. Decreases in bone mass were observed as a result of 
pathway inhibition, although the relative impact on bone formation and resorption 
varied, reflecting the complex fine tuning of the WNT regulatory network. 
2.8.4 WNT β-catenin signalling pathway and osteoarthritis 
The joint is a complex organ composed of different tissues (articular 
cartilage, subchondral bone, joint capsule, synovial membrane and soft tissue 
structures like ligaments, tendons, and meniscus). A number of factors (mechanical 
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and biochemical) act in a synergistic fashion to maintain homeostasis. OA is a 
common disease and is manifested by swelling, joint pain, inflammation and 
progressive loss of function. Considering this, there has been increasing attention 
targeted towards understanding the biology, mechanisms and pathways of the bone-
cartilage unit driving this disease progression with modulation of these pathways as a 
target to slow or retard the disease progression.  
A number of animal experiments, clinical samples and genetic studies 
indicate that WNT is critically involved in the progression of OA [27, 164, 165].  
Genomic studies from twins and siblings suffering with OA show WNT antagonists 
such as FRZB also known as sFRP-3 to be associated with OA howver FRZB knock 
out animals also reveal the complexity of WNT signalling in joint homeostasis [166, 
167]. Further, FRZB-/- mice induced with OA and were found to be more prone to 
loss of proteoglycans from the articular cartilage of the knee with increased cortical 
mineral content and thickness, resulting in stiffer bones. These effects were in 
contrast to the changes seen in LRP5-/- mice [168]. Therefore, results from FRZB-/- 
mice experiments suggest an increased WNT signalling with a negative effect on the 
cartilage.   
AXIN2 is a target gene in the WNT β-catenin signalling pathway and is 
implicated in OA. However, literature reveals that the expression and production of 
AXIN2 leads to the binding of AXIN2 to other molecules (GSK3/APC) and causes 
the phosphorylation of  β-cateninwhich is degraded in a proteosome complex 
Osteoblast proliferation and differentiation were significantly increased and 
osteoclast formation was significantly reduced in AXIN2 Knock-out mice [169].     
Like SOST and FRZB, DKK1 is a soluble inhibitor and a master regulator of 
the WNT signalling pathway, playing a balancing role where increased expression 
is associated with bone resorption and decreased expression is associated with bone 
formation. DKK1-/- mice die because of failure of head induction [170] and 
DKK1+/- mice show increased bone formation without any changes to bone 
resorption [171]. Evidence from blocking TNFα and DKK1 in hTNFtg mice, shows 
that DKK1 can regulate osteophyte formation [172]. The appearance of osteophytes 
upon blockage of DKK1 identifies WNT signalling as a key trigger in the formation 
of osteophytes. This concept is also fostered by consistent results in two other 
models of inflammatory arthritis, CIA and GPI-induced arthritis. These showed 
rapid emergence of osteophytes upon blockade of DKK1 [172] however, their role 
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and levels of expression in OA have been debated [173]. Increased expression of 
plasma and synovial DKK1 was reported and their levels inversely correlated with 
the radiographic severity with knee OA patients [174]. The protective and 
deleterious roles of DKK1 and its association with tissue expression is not known 
to date  [154], however, DKK1 is well evidenced to be a negative regulator of bone 
formation and may indirectly influence osteoclastogenisis. These results indicate a 
close relationship of inflammation and osteophyte formation in OA. Literature also 
shows that mechanical injury up regulates WNT target genes in the bone. In 
addition, microarray gene expression profiling of OA bone tissue reveals activation 
of the WNT signalling pathway [175].  
2.8.5 Osteocyte WNT signalling in bone homeostasis and osteoarthritis  
Significant progress has been made in understanding the role of WNT β-
catenin pathway in osteogenesis and in particular in osteoblast biology. However, 
much less is known about osteocytes in this pathway. Osteocyte biology research is 
becoming prominent with new evidence suggesting that osteocytes use the WNT β-
catenin signalling pathway to communicate and control bone mass, confirming that 
osteocytes are the key regulators of bone homeostasis [29].  
Summarising  sections 2.5.4 and 2.8.3, the WNT signalling pathway has been 
closely linked to hampered cartilage-bone homeostasis, mineral metabolism and 
inflammation in OA  [27, 173]. However, no targeted approach for therapy has been 
elucidated [176-178]. It is now evident that osteocyte  β-cateninsignalling is 
specifically required for normal bone homeostasis [29, 179].  Osteocytes appear to 
use  β-cateninpathway to transmit signals to cells on the bone surface. Recent 
evidence also suggests that osteocytes may be triggered by cross-talks with different 
pathways that respond to loading, leading to decreased expression of negative 
regulators of bone formation such as SOST and DKK1 [172, 180]. Mechanical injury 
down regulates  β-cateninin joints [27, 181]. Studies have shown that WNT β-catenin 
signalling is activated as a result of mechanical loading on osteocytes and is a major 
signalling pathway for mechanotransduction [29]. This pathway has also been 
implicated in osteocyte survival and osteocyte apoptosis correlating with the 
increased osteoclast recruitment and bone resorption [182, 183]. Osteocyte WNT β-
catenin signalling also cross-talks with other signalling pathways to signal between 
bone cells and this cross-talk has been illustrated in Figure 2-11. 
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Figure 2-10 Impact of WNT β-catenin signalling on bone cells 
 
WNT β-catenin signalling is required for the commitment of mesenchymal stem cells to the 
osteoblastic lineage and further its proliferation and differentiation to form osteocytes.  WNT β-
catenin signalling pathway is also required for the expression of the anti-osteoclastic factor OPG by 
osteoblasts and osteocytes (Adapted from [26]). 
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Figure 2-11 Signalling between bone cells to maintain homeostasis 
 
Bone formation is controlled by osteocytes via the WNT signalling antagonists SOST and DKK.The 
expression of these antagonist are regulated by PTH and BMP. PTH represses, whereas BMPR1A-
mediated BMP signaling induces, expression of these antagonists. Osteocytes also control the 
expression of OPG via the WNT signalling pathway. In a feedback loop for bone remodeling, 
osteoclasts stimulate the local differentiation of osteoblasts at the end of the resorption phase by 
secreting WNT ligands. (Adapted from [26]).  
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3.1 ABSTRACT 
Introduction: Subchondral bone sclerosis is a well-recognised manifestation of 
osteoarthritis (OA).  The osteocyte cell network is now considered to be central to 
the regulation of bone homeostasis; however, it is not known whether the integrity of 
the osteocyte cell network is altered in OA patients. The aim of this study was to 
investigate OA osteocyte phenotypic changes and its potential role in OA 
subchondral bone pathogenesis.  
Methods: The morphological and phenotypic changes of osteocytes in OA samples 
were investigated by micro-CT, SEM, histology, immunohistochemistry, TRAP 
staining, apoptosis assay and real-time PCR studies. 
Results: We demonstrated that in OA subchondral bone, osteocyte morphology was 
altered showing rough and rounded cell body with fewer and disorganized dendrites 
compared with the osteocytes in control samples. OA osteocytes also showed 
dysregulated expression of osteocyte markers, apoptosis, and degradative enzymes, 
indicating that phenotypical changes in OA osteocytes could be responsible for OA 
subchondral bone remodelling (increased osteoblast and osteoclast activity) and 
increased bone volume with altered mineral content. 
 Conclusion: Significant alteration of OA osteocytes was identified in OA samples, 
indicating a potential regulatory role of osteocytes in subchondral bone remodelling 
and mineral metabolism during OA progression.  
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3.2 INTRODUCTION 
Osteoarthritis (OA) is the most common musculo-skeletal disorder yet still the 
aetiology is unknown. Regardless of the aetiology the disease is progressive and is 
characterised by a series of predictable clinical and radiological changes. More than 
30 years ago, Radin et al suggested that an increase in stiffness of subchondral bone, 
rendering it less capable of attenuating and distributing load throughout the joint, 
increased stress in the overlying articular cartilage, leading to the deterioration in OA 
[1, 184]. One of the earliest changes seen radiographically, often before any joint 
space narrowing is observed, is subchondral bone sclerosis. This sclerosis is 
recognised as a radiographic sign of OA but its significance has been little explored. 
Subchondral bone is made up of a specialized connective tissue formed by a 
mineralized matrix containing specific type I collagen, proteoglycans, and several 
growth factors, as well as bone specific cell types: osteoblasts, osteocytes, and 
osteoclasts. It has been reported that OA subchondral bone shows dysregulated 
osteoblast [185] and osteoclast phenotype [186]. However, it is currently not known 
whether osteocyte cells undergo phenotypic changes during OA progression.  
Osteocytes are terminally differentiated osteoblasts and they reside within the 
mineralized bone matrix and make up more than 90-95% of all bone cells in the adult 
skeleton. The osteocyte-canalicular cell network is now considered to play a central 
and multi-functional role in regulating skeletal homeostasis [187]. The most accepted 
theory for osteocytic function places these cells as transducers of mechanical strains 
that are translated into biochemical signals affecting the communication among 
osteocytes and between osteocytes and osteoblasts or osteoclasts [188]. This cascade 
of events may ultimately regulate bone remodelling and mineral metabolism [189]. 
Since mechanical knee misalignment and altered joint geometry were known causes 
of OA [190], it is likely that osteocytes might undergo enormous changes given their 
function is to act as transducers of mechanical strains. 
This study was designed to understand the pathophysiology of osteocyte 
network in OA patients by determining changes in osteocyte morphology, 
distribution, apoptosis, and evaluating the expression of osteocyte makers and matrix 
degradation enzymes. It was noted that phenotypic changes of osteocytes in OA 
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patients induced active site-specific remodelling of subchondral bone resulting in 
subchondral bone thickening and dysregulated mineral metabolism. 
3.3 MATERIALS AND METHODS 
Patients 
OA patients undergoing total knee replacement were recruited for this study after 
informed consent was given.  This study was approved by The Queensland 
University of Technology and Prince Charles Hospital ethics committees. Patient 
variables i.e., height, weight and age were recorded and preoperative radiographs of 
the knee, anteroposterially and laterally, were taken. The Subchondral bone was 
classified using scoring system set by The American College of Rheumatology 
[191]. OA cartilage was classified according to the modified Mankin score [192]. 
According to the previous studies [185], the patients were classified as OA (n=5) 
with a Mankin score greater than 5 and control (n=5) with a score less than 3.  
Micro-CT 
Morphological changes of subchondral bone in control vs. OA specimens were 
determined using Micro-CT. Tibial plate samples were scanned with micro CT 
(Scanco 40, Switzerland) with isotropic voxel size of 18 μm after tissues were fixed 
in 4% paraformaldehyde (PFA) in PBS as scanning medium. The x-ray tube voltage 
was 55 kV and the current was 145 μA, with a 0.5 mm aluminium filter. The 
exposure time was 1180 ms. The data set was segmented with an inbuilt software. In 
the medial and the lateral part of each tibia, a volume of interest (VOI) was selected 
with automatic contouring method. The circles were located in the middle of the 
load-bearing and non-load bearing sites of subchondral bone areas. Selected areas 
contained subchondral plate, but did not contain subchondral trabecular bone or 
growth-plate tissue. A total of 30 consecutive tomographic slices were analysed. The 
meaningful subchondral bone plate measurements such as bone volume (mg 
HA/ccm) and BV/TV (%) were analysed using inbuilt software. Subchondral bone 
thickness was measured quantitatively using Axio Vision software by converting 
number of pixels to micro meters.   
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Scanning electron microscopy (SEM) analysis for osteocytes 
SEM and backscatter SEM was performed as described previously [193]. For resin-
casted SEM, samples were dissected and fixed in 2.5% glutaraldehyde in 0.1 M 
sodium cacodylate buffer containing 0.05% tannic acid. The tissue specimens were 
dehydrated in ascending concentrations of ethanol (from 70% to 100%), embedded 
in methyl methacrylate, and then surface polished using 1 μm and 0.3 μm Alpha 
Micropolish Alumina II (Buehler) in a soft-cloth rotating wheel. The bone surface 
was acid etched with 37% phosphoric acid for 2–10 seconds, followed by 5% sodium 
hypochlorite for 5 min. The samples were then coated with gold and palladium as 
described previously [194] and examined using an FEI/Philips XL30 Field-Emission 
Environmental Scanning Electron Microscope. 
For back-scattered SEM (BSEM), the samples were fixed overnight in 2% 
paraformaldehyde and 2% glutaraldehyde buffered at pH 7.4 with 0.1 M sodium 
cacodylate. Samples were then rinsed three times (20 min each time) in 0.1 M 
cacodylate buffer solution followed by secondary fixation (1 h) in a solution of 1% 
osmium tetroxide in 0.1 M cacodylate buffer. The BSEM samples were then coated 
with carbon and examined using an FEI/ Philips XL30 Field-Emission 
Environmental Scanning Electron Microscope. 
Histology tissue preparation 
All samples containing any overlying cartilage and subchondral bone were dissected 
to an approximate depth of 1cm. All of the samples for histology and 
immunohistochemical analysis were washed in saline and immediately fixed in 4 % 
paraformaldehyde for 24 hours. The samples were washed in phosphate buffer 
solution (PBS) for one hour and then placed in 10% ethylene diamine tetraacetic acid 
(EDTA) for decalcification. The EDTA solution (PH 7.0) was changed weekly for 
four weeks and decalcification was confirmed by radiographic analysis. Tissue 
specimens were embedded in paraffin wax once the decalcification was complete. 
Tissue slices of 5 µm thick were sectioned using microtome, placed on 3-
aminopropyltriethoxy-silane coated glass slides, air-dried and stored at 4°C prior to 
analysis. Each specimen was H&E stained to visualize the general morphology.   
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H&E staining 
Tissue slices were dewaxed in xylene and dehydrated in descending concentrations 
of ethanol (100% to 70%), sections were then stained with Mayers’s haemotoxylin 
for 1-2 minutes before washing with tap water for 5 minutes. The slides were 
dehydrated in ascending concentration of ethanol (70% to 100%) and stained with 
eosin for 15 seconds and cleared with xylene and mounted on DePeX mounting 
medium (BDH Laboratory Supplies, England). 
Immunohistochemistry 
Immunohistochemistry was carried out using an indirect immunoperoxidase method. 
Tissue slices were dewaxed in xylene and dehydrated. Endogenous peroxidases were 
blocked by incubation in 0.3% peroxide for 30 min followed by repeated washing in 
PBS. The sections were then incubated with proteinases K (DAKO Multilink, CA, 
USA) for 20 min for antigen retrieval. Next, all sections were treated with 0.1% 
bovine serum albumin (BSA) with 10% swine serum in PBS. Sections were then 
incubated with optimal dilution of primary antibody overnight at 4 °C. Optimum 
concentration of antibody was determined by using a series of dilutions.  After 24 
hours, sections were incubated with a biotinylated swine-anti-mouse, rabbit, goat 
antibody (DAKO Multilink, CA, USA) for 15 min, and then incubated with 
horseradish perioxidase-conjugated avidin-biotin complex for 15 min. Antibody 
complexes were visualized by the addition of a buffered diaminobenzidine (DAB) 
substrate for 3 min and the reaction was stopped by rinsing sections in PBS. Sections 
were counterstained with Mayer’s haematoxylin for 10 sec each, and rinsed with 
running tap water. Following this, dehydrated with ascending concentrations of 
ethanol solutions, cleared with xylene and mounted with coverslip using DePeX 
mounting medium. Controls for the immunostaining procedures included conditions 
where the primary antibody and the secondary (anti-mouse IgG) antibodies were 
omitted. In addition, an irrelevant antibody (anti CD-15), which was not present in 
the test sections, was used as a control. A list of antibody sources and dilutions used 
for this study are summarized in Table 3-1.  
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Table 3-1 A list of antibodies, sources and working dilutions used for immunohistochemistry 
 
Protein  Dilution  Source  
Sclerostin  1:100 Gift from Prof Jian Q Feng 
DMP-1  1:1000 Gift from Prof Jian Q Feng  
MMP9  
RB1539-PO 1:250  Labvision, Fremont, CA 
ADAMTS4  
RB1442-PO 1:100 Labvision, Fremont, CA 
MMP1 
AB52631 1:200 Labvision, Fremont, CA 
 
Distribution of osteocyte cell number and lacunae 
Subchondral bone plate was defined as starting from the calcified cartilage (CC) 
bone junction and ending at the marrow space. Meaningful parameters to describe 
our area of interest were determined by measuring the thickness of the subchondral 
plate in all samples under 10 x magnification and calculating the average length 
(0.98mm) and calculating the average area. Average osteocyte nucleus (Avg OS.N) 
and average osteocyte empty lacunae (Avg OS.L) were counted per unit area, within 
the defined area of interest using AxioVision Rel 4.8 Software. The Avg OS.N and 
Avg OS. Lac  between control and OA are represented in a bar graph.  
In situ cell death detection (apoptosis) using TUNEL 
Osteocyte apoptosis was assessed principally at single cell level, based on labelling 
of DNA strand breaks (Terminal deoxynucleotidyl transferase dUTP nick end 
labelling or TUNEL technology) using In Situ Cell Death Detection Kit, Fluorescein  
(Roche, Germany) according to manufacturer’s protocol. Tissue sections were 
permeabilised for 30min at 37 °C with Proteinase K solution (Roche, Germany). As a 
positive control, sections were treated with DNase1 for 10 min at room temperature 
prior to labelling procedure was used to induce DNA strand breaks. The TUNEL 
reaction mixture / terminal transferace was omitted for the negative control. 
Subchondral bone plate was defined as starting from the calcified cartilage (CC) 
bone junction and ending at the marrow space. Meaningful parameters to describe 
our area of interest were determined by measuring the thickness of the subchondral 
plate in all samples under 10 x magnifications and calculating the average length  
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(0.98 mm) and calculating the average area. TUNEL positive osteocytes were 
counted in 3 fields per section within the defined area of interest using AxioVision 
Rel 4.8 Software. The average TUNEL positive osteocyte between control and OA 
are represented in a bar graph. 
Quantitative real time polymerase reaction (qPCR) 
qPCR was performed to detect the gene expression differences in control and OA 
bone lysates. Briefly, for total RNA extraction, the fresh bone tissues were obtained 
from OA patients (collected in RNAse later solution) and graded according to the 
disease severity. Small fragments of bone were cut by using a bone cutter and tissues 
were homogenised using a bead beater for one minute. Total RNA was extracted 
using the Trizol method and qPCR was performed as described previously [2, 195]. 
The quality and integrity of the RNA extracted were confirmed on 1% wt/vol 
ethidium bromide-stained agarose gels.  
Western blot  
Total tissue protein was harvested by lysing the subchondral bone in a lysis buffer 
containing 1 M Tris HCl (pH 8), 5 M NaCl, 20% Triton X-100, 0.5 M EDTA and a 
protease inhibitor cocktail (Roche, Dee Why, NSW, Australia). The cell lysate was 
clarified by centrifugation and the protein concentration determined by a 
bicinchoninic acid protein assay (Sigma-Aldrich). 10 g of protein was separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis on a 12% gel. The protein 
was transferred to a nitrocellulose membrane, and blocked in a Tris-Tween buffer 
containing 5% non-fat milk. The membranes were incubated with primary antibodies 
against ALP (1:1,000) and OCN (1:2,000) overnight at 4ºC. The membranes were 
washed three times in TBS-Tween buffer, and then incubated with an anti-rabbit 
secondary antibody at 1:2,000 dilutions for 1 hr. The protein bands were visualized 
using the ECL Plus™ Western Blotting Detection Reagents (GE Healthcare, 
Rydalmere, NSW, and Australia) and exposed on X-ray film (Fujifilm, Stafford, 
QLD, Australia).  Immunoblot negatives were analyzed by densitometry using Image 
J software. 
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Tartrate resistant acid phosphatase (TRAP) staining of paraffin embedded 
samples  
To detect osteoclast activity, TRAP staining was performed as described previously 
by Erlebacher et al [196]. Paraffin sections of 5 μm thickness were deparaffinised in 
two changes of xylene (8 min each) and rehydrated (2 changes 95% ethanol, 2 min 
each; 1 change 70% and 50% ethanol each 5 min, deionised water 5 min). After 
rehydration, samples were placed in 0.2 M Acetate Buffer (0.2 M sodium acetate and 
50 mM L(+) tartaric acid in ddH2O, pH 5.0) for 20 min at room temperature. 
Subsequently sections were incubated with 0.5 mg/ml naphtol AS-MX phosphate 
(Sigma) and 1.1 mg/ml fast red TR salt (Sigma) in 0.2 M acetate buffer for 1-4 h at 
37ºC until osteoclasts appeared bright red. Samples were counterstained with 
Haematoxylin, air dried and mounted with ProLong® Gold (Invitrogen) mounting 
solution. 
Statistical analysis 
Paired Student’s t-test was used to determine any significance between control vs. 
OA subchondral bone, by counting the % positive staining cells in the field of view 
for immunohistochemistry, by counting the Avg OS.N and Avg OS.L (per unit area), 
and for distribution studies.  p ≤ 0.05 was considered significant.  
 
3.4 RESULTS 
Patient Demographics and specimen characterization  
The mean age of all patients was 72 years (range 63 – 79), mean weight was 
93.4 kg (range 64-105) and mean height was 173 cm (range 162-185). H&E staining 
was performed to confirm the site specific changes in the samples. All control 
specimens showed normal appearing articular cartilage with underlying subchondral 
bone. The outer (radial) layer of noncalcified cartilage (NC) was separated from the 
underlying calcified cartilage (CC) layer by the tidemark (TM). Immediately 
adjacent to the CC was the subchondral bone plate (SB). In contrast, OA specimens 
showed cartilage loss with a small region on the edge of the slide where there was 
some preservation of the deep and middle zone cartilage layers. The NC was much 
thinner and the CC was relatively thicker in OA samples when compared to the 
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control specimens. Therefore, the distance between the TM and the SB was thicker 
than in the normal specimens. SB advancement in the OA specimens was seen in all 
the patients indicating extensive bone remodeling. Collectively, these results show 
significant site-specific changes in OA patients. 
Altered gene expression, micro-architectural and mineral properties in OA 
subchondral bone 
A representative of the 3-D reconstruction of subchondral bone from micro-
CT images (Figure 3-1a, i-ii) showed significant changes in the microstructure of 
subchondral bone in OA patients. Compared with control, OA subchondral bone was 
significantly thicker and denser with a plate-like structure. Quantitative micro-CT 
data revealed that OA specimens had a 20% increase in bone volume fraction 
compared to the control group (p = 0.049) (Figure 3-1a, iii). Similarly, an increase in 
the subchondral bone thickness and mean density was observed in OA patients 
(Figure 3-1a, iv-v). To further investigate these at the molecular level, it was noted 
that the mRNA (Figure 3-1b, i-iii) and protein (Figure 3-1b, iv) synthesis of alkaline 
phosphatase (ALP), osteopontin (OPN) and osteocalcin (OCN) were significantly 
higher in OA samples compared to patient matched controls. These results indicate 
abnormal site-specific OA bone phenotypic properties. Goldner’s trichrome staining 
showed that there were statistically significantly increased un-mineralized areas 
(stained orange) in OA subchondral bone compared with controls (Figure 3-1c, i-ii). 
This was further confirmed by Von kossa staining on the un-decalcified tissue 
samples, which showed that the mineral content distribution was statistically 
significantly altered in OA subchondral bone, showing increased less mineralized 
areas compared with controls (Black staining shows the distribution of mineral 
content and white shows the distribution of un-mineralized areas) (Figure 3-1c, iii-
iv). Similarly, backscatter SEM images showed significantly disorganized mineral 
distribution compared with the controls where the white/grey areas show the 
distribution of mineral content and the black areas show the lack of mineral content 
(Figure 3-1c, v-vi).   
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Distorted osteocyte distribution and morphology in OA samples  
A representative H&E staining of the subchondral bone of OA and patient 
matched control shows the histological appearance of osteocyte morphology, number 
and distribution. Arrows represent osteocyte nucleus and arrow heads represent 
empty osteocyte lacunae (Figure 3-2a, i-ii). Average osteocyte lacunae (Avg.OS.Lac) 
density was significantly increased in the OA patients compared to controls   (p = 
0.0041). However, no significant differences were observed with respect to Average 
osteocyte nucleus (Avg.OS.N) (p=0.0691) or viable osteocyte count (Figure 3-2a, iii-
iv).  We examined the morphology of OA osteocytes using back scatter SEM (Figure 
3-2b, i-ii) and SEM (Figure 3-2b, iii-vi) and it revealed that the osteocytes in OA 
samples were markedly deformed with a rough, lysed (Figure 3-2b, iv&vi) and 
rounded appearance (Figure 3-2b, ii) with very few dendrites compared to spindle 
shaped (Figure 3-2b, i), well organised and well connected osteocytes (Figure 3-2b, 
iii&v) in the control specimens. Furthermore, mineral distribution was disorganised, 
showing woven appearance in OA (Figure 3-2b, ii) compared with well organised 
and consistent mineral distribution in normal samples (Figure 3-2b, i). Blood vessel 
invasion in OA subchondral bone was also observed (Figure 3-2b, iv).  
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Figure 3-1  Micro-architectural and mineral properties in OA subchondral bone 
 
 A representative 3-D reconstructions of tibial bone specimens of control and OA from micro-CT 
scans (figure 3-1a, i-ii) and quantitative results show OA subchondral bone plate has a higher bone 
volume fraction, mineral content and thickness compared to control specimens (figure 3-1a, iii-v) . 
Molecular marker changes: qRT-PCR was used to measure the gene expression levels of ALP, OPN 
and OCN. ALP and OPN showed a significant increase in OA bone (figure 3-1b, i-iii), Bars equals 
mean±SD, n=5, y-axis is the relative expression. At the protein level, a similar trend was observed 
using western bolt (figure 3-1b, iv). Tubulin was used as an internal loading control. *p≤0.05. Goldner 
staining of control and OA samples (figure 3-1c, i-ii). Von kossa stained sections (figure 3-1c,iii-iv). 
Back scatter SEM (BS-SEM) images (figure 3-1c, v-vi). 
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Figure 3-2 Disrupted osteocyte morphology and distribution in OA patients 
 
H&E staining of the subchondral bone of OA and patient matched control showing the histological 
appearance of osteocyte morphology, number and distribution. Arrows represent osteocyte nucleus 
and arrow heads represent osteocyte lacunae (Figure 3-2a, i-ii).  OA subchondral plate showed no 
significant increase in the Avg OS.N (p=0.0691) compared to control (Figure 3-2a, iii). OA 
subchondral plate showed a significant increase in the Avg OS.Lac (p=0.0041) compared to control 
(Figure 3-2a, iv). Bars equal mean±SD, n=5, *p≤ 0.05.(Figure 3-2b, i-ii) Back scatter image and 
(Figure 3-2b, iii-vi) SEM images show clear morphological differences which include rough lysed and 
rounded appearance with fewer dendrites in OA osteocytes and blood vessel (arrows) invasion in OA 
samples (Figure 3-2b, iv). 
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Dysregulated osteocyte markers in OA osteocytes:  
 
Osteocytes selectively express sclerostin (SOST), which is well characterised 
as negative regulator of bone formation. We performed a comparative 
immunohistochemical analysis of SOST expression in OA and patient matched 
control samples. When quantified by assessing the percentage fraction of SOST-
positive osteocytes among total osteocytes, major differences became evident. SOST 
expression was observed in more than half of the osteocytes in the control specimens 
but was significantly reduced in OA samples (p=0.001), indicating a suppressed 
expression of this bone regulatory protein in OA (Figure 3-3, a-b). In contrast to 
these findings the expression of Dentin Matrix Protein 1 (DMP1, regulator of bone 
mineralisation) staining was stronger in OA osteocytes and the percentage of DMP1 
positive osteocytes were higher in OA compared to control specimens (p=0.0002) 
(Figure 3-3, d-e). The expression of DMP1 and SOST has been correlated to the ratio 
of bone volume to total volume (BV/TV) showing that increase in bone volume was 
correlated with the expression of increased DMP1 and decreased SOST (Figure 3-3, 
c&f).  
Increased apoptosis and TRAP positive staining in OA osteocyte  
The number of average TUNEL and TRAP positive osteocytes was 
significantly higher in OA osteocytes compared to controls. In OA subchondral bone 
there were increased osteoclast activity showing TRAP positive (Figure 3-4a, ii) 
compared to the control (Figure 3-4a, i). Interestingly, osteocytes in OA samples also 
showed positive staining of TRAP (Figure 3-4a, iv) compared with the controls 
(Figure 3-4a, iii), where osteocytes showed negative TRAP staining. A representative 
TUNEL stained section showed more number of osteocytes undergoing apoptosis in 
OA samples (figure 3-4b, ii) compared to controls (Figure 3-4b, i). The average 
TUNEL positive osteocyte between control and OA are represented in a bar graph 
(Figure 3-4b, iii).  
Dysregulated expression of degradative enzyme expression in OA osteocytes  
Matrix metalloproteinases (MMPs) are well recognized as mediators of 
matrix degradation, and their activity by virtue of the cleavage of matrix substrates 
are well known. We showed that the intensity of MMP-1. (Figure 3-5, a-c), MMP-9 
(Figure 3-5, d-f), and ADAMTS4 (Figure 3-5, g-i) signals were stronger and the 
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percentage of positive osteocytes were significantly higher in OA samples compared 
to control patient specimens. 
 
 
 
Figure 3-3 Expression of osteocyte markers and the correlation to BV/TV 
 
Immunohistochemical analysis shows a decrease in the average % positive stained osteocytes for 
SOST in OA patients compared to controls (p=0.001) (Figure 3-3, d-e).  and an increase in the 
average % positive stained osteocytes for DMP1 in OA patients compared to controls (p=0.003) 
(Figure 3-3, a-b) Correlation studies reveals that the expression of SOST decreases with the increase 
in bone volume to total volume (BV/TV) (Figure 3-3, c) and the expression of DMP1 increases with 
increase in BV/TV (Figure 3-3, f). 
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Figure 3-4 Defective osteoclast / osteocyte TRAP expression and increased apoptosis (TUNEL 
positive) in OA osteocytes 
 
A representative TRAP stained section shows an increased in the number of osteoclasts (Figure 3-4a, 
i-ii). Increased TRAP positive osteocytes were observed in OA subchondral bone (Figure 3-4a, iii-iv). 
A representative TUNEL stained section shows that increased number of OA osteocytes are 
undergoing apoptosis compared to controls. Arrows represent TUNEL positive osteocytes and arrow 
heads represents live/nuclear stain (Figure 3-4, i-ii). Figure 3-4b, iii is the bar graph showing increased 
TUNEL positive OA osteocytes. Bars equal mean±SD, n=5, *p≤ 0.05. 
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Figure 3-5 Dysregulated expression of degradative enzymes 
 
Significant increase in the average percentage positive stained osteocytes in OA samples was 
observed with (Figure 3-5, a-c) MMP1 (p=0.001), (Figure 3-5, d-f) MMP9 (p=0.0026), (Figure 3-5, g-
i) ADAMTs4 (p=0.0042) compared controls. Scale bars = 20μ; Bars on graphs = mean±SD, (n=5), 
*p≤ 0.05. 
 
3.5 DISCUSSION 
Subchondral bone sclerosis is a major patho-physiological manifestation of 
OA, and it is still unknown if it precedes cartilage breakdown in this disease. 
Regardless of whether bone sclerosis is the initiating event, it perturbs the overlying 
cartilage in OA patients; therefore, preventing subchondral bone sclerosis may 
contribute to improving the comfort and mobility of OA patients [11]. It is evident 
that subchondral bone cells such as osteoblasts and osteoclasts undergo significant 
changes in OA [19]. However, recent studies emphasise the importance of osteocyte 
in maintaining the bone homeostasis. Studies have demonstrated that osteocytes 
regulate the behaviour of osteoblasts and osteoclasts by communicating through gap 
junctions [197]. With this evidence, we hypothesised that osteocyte function may be 
hampered in OA leading to an OA osteocyte phenotype and this could play an 
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important pathological role in subchondral bone sclerosis. Our findings suggest that 
the various functional properties of osteocytes appear to be changed in patients with 
OA.   
In OA, the increase in bone volume, density, and stiffening of subchondral 
bone has been reported and the possible reason for this change might be due to bone 
remodelling in response to repetitive micro-damage/fracture as a result of an 
imbalance in mechanical loading of the joint [56]. In this study we identified that OA 
subchondral bone showed an increased bone volume and the bone mineral content 
was significantly altered. We further demonstrated that these subchondral bone 
changes in OA were correlated with the expression of osteocyte markers, which 
showed decreased SOST and increased DMP1 expression in OA samples. Osteocyte 
expression of SOST is a delayed event and it is produced only by mature osteocytes 
after they become embedded in matrix that has been mineralized. From then on, 
mature osteocytes appear to express SOST whether they are located in bone. SOST 
knockout mice have a progressive high bone mass phenotype [95, 198]. The precise 
physiological role of SOST in osteocytes is not yet fully understood, but numerous 
studies indicate that loss of SOST expression enhance osteogenesis [87]. Currently, it 
is thought that SOST passes through the osteocytic canalicular network to the bone 
surface where it inhibits osteoblastic canonical WNT β-catenin signaling, which is 
implicated in bone mass regulation [96, 199, 200]. Therefore, decreased SOST 
expression in OA osteocytes may be responsible for the increased bone volume in 
OA subchondral bone.  
In contrast to the expression of SOST, increased expression of DMP1 can 
induce impairment in mineralization [201, 202] with poorly organized mineral and 
an apparent delay in the transition from osteoblasts to osteocytes. In this study it was 
found that OA subchondral bone showed significant dysregulation in mineral 
metabolism. This may be due to the increased expression of DMP1 in OA osteocytes. 
DMP-1 is a secretory protein and an osteocyte marker essential for normal postnatal 
chondrogenesis and subsequent osteogenesis [203]. In vivo studies show that DMP1 
actively participates in bone homeostasis and mineralization. In addition, mechanical 
loading stimulates dentin matrix protein 1 (Dmp1) expression in osteocytes [86, 204, 
205]. It can be assumed that increased expression of DMP1 in OA osteocytes may 
disrupts the normal mineralization process in OA subchondral bone, resulting 
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increased osteoid volume and irregular mineralization of OA subchondral bone. The 
surprising finding of decreased SOST and increased DMP1 expression in OA 
osteocytes may be indicative of elevated bone turnover resulting in increased 
subchondral bone volume in OA samples, a characteristic feature of OA. Indeed, we 
demonstrated that bone turnover markers (ALP, OPN, OCN, MMPs, and TRAP) 
were significantly up regulated in OA samples compared with controls, indicating an 
underlying potential mechanism of osteocytes in OA subchondral bone changes. This 
also may indicate defective osteocyte phenotype in OA progression to produce 
SOST, instead with more DMP1 production.  
Osteocytes and the connections among them are highly dynamic, as 
evidenced by constant contraction and expansion of osteocyte bodies within the 
lacunae and by the extension and retraction of dendrites thus adapting to mechanical 
load [206] . This may imply that the shape of osteocytes is determined by external 
loading and imbalanced mechanical stimulation can lead to morphological changes. 
Our SEM results showed that OA subchondral bone osteocytes (OA osteocyte 
phenotype) were more sphere-shaped, rough and were not aligned in any particular 
direction. However, the patient matched control osteocytes (Normal osteocyte 
phenotype) showed stretched shape and aligned distribution. These results indicate 
that an irregular morphology of osteocytes might predispose OA that might alter the 
ability of bone to sense mechanical stimuli leading to significant changes in the 
structure and mineral density. It could be interpreted as phenomena where the signals 
passing through osteoblasts and osteoclasts could be hampered. Indeed, increased 
osteogenic activities (ALP, OPN and OCN expression) and increased osteoclastic 
activity (TRAP staining) were noted in OA subchondral bone. 
An adequate number of osteocytes are essential to remove bone 
microdamage, and the osteocyte density correlates with the quality of bone [207]. In 
this study we found that average osteocyte lacunae (Avg.OS.Lac) number was 
significantly higher in OA bone compared to normal’s, however no significant 
differences were observed with respect to total number of osteocyte nucleus count. 
This could be explained by the increased osteocyte apoptosis, showing TUNEL 
positive osteocytes in OA samples.  
Our results clearly showed that rough, lysed and rounded appearance of the 
lacunae and canaliculi of osteocytes in OA samples. To adapt to mechanical stimuli,  
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osteocytes modulate their own mechanical environment through increase and 
decrease in its attachment to the matrix [208]. MMPs are well recognized as 
mediators of matrix degradation, and their activity by virtue of the cleavage of matrix 
substrates are well known. As expected we found that MMP-1, MMP-9 and 
ADAMTS4 were all significantly increased in OA compared to control samples 
giving a possible indication to assume that the osteocyte morphology will corrode its 
coupling to the matrix by producing digesting enzymes such as MMPs. The function 
of osteocyte through death and the expression MMPs in bone remodelling and joint 
disease has been emphasised in various independent research [209-211]. Role of 
osteocytes in the regulation of bone resorption has been largely unknown. TRAP 
staining has been regarded as one of the reliable markers of osteoclasts. Few studies 
have shown the expression of TRAP in osteocytes close to the bone resorbing surface 
and its relation to MMPs [212-214]. With this in view, TRAP positive and MMPs 
positive osteocytes could be viable and it could control the direction of osteoclastic 
resorption in OA subchondral bone. However, these results need further investigation 
to understand the cellular interactions between TRAP positive osteocytes and 
osteoclasts during bone resorption.  
 
3.6 CONCLUSION 
Our study provides evidence that OA osteocyte phenotype has distinctive 
changes both phenotypically and morphologically. We conclude that the OA 
osteocyte phenotypic changes are responsible for the OA subchondral bone 
pathogenesis that could be caused by the activation/deactivation of osteocyte 
signalling molecules in the OA microenvironment.  
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4.1 ABSTRACT 
Introduction Subchondral bone sclerosis is recognized as a clinical sign in 
osteoarthritis (OA). Although osteocytes play a central role in regulating bone 
remodelling, their involvement in OA subchondral bone pathophysiology is poorly 
defined. Our recent studies suggest that dysregulated osteocytic proteins contribute to 
the pathological changes in subchondral bone of OA patients. The aim of this study 
was to investigate whether surgically induced rat OA model (medial minesectomy) 
could induce similar subchondral bone changes identified at the clinical situation. 
Methods OA was induced in twelve week-old Wistar Kyoto rats by the removal of 
the medial meniscus (MSX). For bone remodelling study, fluorochrome calcein was 
injected 6 weeks post-surgery intraperitoneally and fluorochrome alizarin was 
injected 10 days after calcein injection. Rats were sacrificed at 8 weeks post-surgery 
and tissue samples were collected and processed by both decalcified and 
undecalcified methods for the study of subchondral bone and osteocyte phenotype by 
micro-CT, scanning electron microscope (SEM), histology and 
immunohistochemistry.  
Results  Increased progression of subchondral bone remodelling was detected in rat 
MSX model with significant accumulation of calcein and alizarin, indicating 
increased net bone formation at both time points of fluorochrome injection in MSX 
surgery compared to the SHAM. Micro-CT and SEM showed high subchondral bone 
volume with altered osteocyte morphology in the MSX group. Further histological 
analysis of the MSX group demonstrated higher numbers of osteocytes expressing 
DMP1, E11, apoptosis, and TRAP compared to SHAM controls, whereas a 
decreased number of SOST expressing osteocytes were found. WNT signalling 
pathway proteins (β-catenin, AXIN2) were significantly increased in MSX 
osteocytes.  Conversely, DKK1 was significantly decreased in MSX osteocytes 
compared to SHAM controls.  
Conclusion These results demonstrated the changes of subchondral bone and 
osteocytes in a rat MSX model, which is similar to human OA, indicating a potential 
regulatory role of osteocytes in subchondral bone remodelling and mineral 
metabolism via WNT β-catenin signalling pathway during OA pathogenesis. 
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4.2 INTRODUCTION 
Joint instability, particularly following trauma, has long been considered a 
predisposition to OA in humans and animals. The key pathophysiological features of 
OA joints include abnormal subchondral bone metabolism and articular cartilage 
degeneration [176]. OA is a heterogeneous condition in which various different 
pathways culminate in a common clinically characteristic joint/organ failure [19, 
111]. OA is one of the oldest known diseases and yet its aetiology is largely 
unknown and widely debated [215]. A fine balance between bone resorption and 
bone formation is required to maintain skeletal homeostasis. In OA, this balance is 
site-specifically altered with hampered mineral metabolism.  
The lack of accurate correlation between characteristic clinical features and 
pathobiological changes of human joints has placed animal models and in vitro 
studies as the corner stone to explore and clarify the molecular pathogenic events that 
occur at onset and progression of OA [116, 216]. These animal models serve also to 
help us better understand this complex, multidisciplinary, organ level disease. These 
models are necessary, dynamic and cannot simply be replaced by in vitro studies 
[215]. Various studies and characterisation of therapeutic targets have been tested on 
different OA animal models including rats due to their similar histopathological 
features to humans and their minimal spontaneous degeneration in knee joints. 
Therefore, the changes in the knee joints can be directly associated to the surgical 
intervention [217].  
The MSX rat model is well characterised and widely used to study the 
detection and progression of OA [218-220] as well as test the efficacy of new 
therapeutic drugs [42, 221]. However, biological, mechanical and pharmaceutical 
investigations have mainly focused on chondrocyte, osteoblast and osteoclast 
changes, not osteocytes.  Osteocytes, the “embedded warriors” make up 90% of the 
bone cells but they are the least studied cell in the literature indicating that their role 
has been  underestimated until now [15, 88]. Several challenges have constrained and 
are still limiting researchers from exploring the role of osteocyte in physiology and 
pathology due to its unique location and morphology [222, 223]. However, research 
in the last few years has focused extensively on osteocytes and places these cells as 
vital communicators, central to the regulation of mineral metabolism and bone  
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remodelling [79, 224]. Given OA is a multifactorial disease with altered joint 
geometry and mechanical knee misalignment, for the first time, our research 
demonstrated that osteocytes undergo dramatic morphological and phenotypical 
changes in human knee OA patients and this could lead to or be the cause of the 
observed altered bone and mineral metabolism [225]; however, it is unknown how 
these changes correlate with the rat menisectomy model, which is routinely used to 
understand OA. Therefore, it is important to understand if the integrity of the 
osteocyte cell network and mineral metabolism is altered in an OA MSX rat model 
and if it closely mimics the human situation to explore and assess the OA disease 
progression. Apart from phenotypic changes, understanding the molecular 
mechanisms such as WNT signalling that govern osteocytes is critical to explore 
disease-modifying drugs.   
WNTs are a family of cysteine–rich, 19 secreted glycoproteins that locally 
activate receptor-mediated signalling pathways. The WNT Signalling pathway and 
its function in bone homeostasis are well documented. WNTs are associated with 
postnatal cartilage differentiation, cartilage matrix catabolism and inhibition of 
chondrocyte apoptosis. In addition, it is known to play an important role by 
controlling differentiation of bone forming osteoblasts and bone resorbing osteoclast 
[149]. Although WNT proteins signal through several pathways, the canonical 
pathway appears to be particularly important for bone biology, its complexities and 
its current understandings in critical aspects of skeletal biology have been reviewed 
by many researchers [150, 151]. However, osteocyte biology research is becoming 
intense with new evidence suggesting that osteocytes use the WNT β-catenin 
signalling pathway to communicate and control bone mass, confirming that 
osteocytes are the key regulators of bone homeostasis  [29]. Adding to this fact, 
WNT signalling pathway has also been closely linked to hampered cartilage-bone 
homeostasis, mineral metabolism and inflammation in OA  [27, 173].  
This study therefore evaluated and assessed the MSX rat model to recapture the 
observed subchondral bone, mineral metabolism and osteocyte phenotype in OA 
patients; and to allow the investigation of subchondral bone, osteocyte changes and 
the involvement of osteocyte WNT β-catenin signalling in OA pathophysiology. 
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4.3 MATERIALS AND METHODS 
Animals and OA induction:  
Animal ethics approval for this project was granted by Queensland University of 
Technology and Prince Charles Hospital Ethics Committees . Male Wistar Kyoto rats 
(12 weeks and weighing approximately 320 g) were purchased from the Medical 
Engineering Research Facility (Brisbane, Australia). The animals were housed under 
conditions that included a controlled light cycle (light/dark: 12 h each), controlled 
temperature (23 ± 1°C), and were allowed to habituate themselves to the housing 
facilities for at least 7 days before surgeries. 
OA was induced surgically by removing the medial meniscus (MSX group-Figure 
4-1, a-c), the medial collateral ligament was transected to open the joint space and 
the meniscus was reflected towards the femur. The meniscus was then cut at its 
narrowest point without damaging the tibial surface resulting in complete medial 
meniscus transection. The surgical wounds were closed by suturing the subcutaneous 
tissue layers using 3/0 Vicryl sutures and the skin was closed using skin staples.  
Induction of general anaesthesia was achieved in an isoflurane chamber (mixture of 2 
lit/min O2 and 5% isoflurane), and anaesthesia was maintained with 2% isoflurane in 
1 lit/min O2 using a rat size nose cone. The left knee was used as the Sham/Control 
group and subjected to the same surgical procedure without the excision of the 
ligament or any meniscus manipulation. The control group was injected with 0.9% 
saline only.  
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Figure 4-1Rat surgery set-up and procedure  
 
Surgery room set up (a); (b-c) Medial menisectomy surgery: The medial collateral ligament was 
transected to open the joint space and the meniscus is reflected towards the femur. The meniscus was 
then cut at its narrowest point without damaging the tibial surface resulting in complete medial 
meniscus transection. (d-f) Rats injected intra-peritoneally with bone markers (calcein and alizarin). 
 
Tissue processing and morphological characterisation 
Whole knee joints were removed by dissection, fixed in 4% paraformaldehyde and 
decalcified in 10% EDTA for paraffin embedding as described previously [225]   and 
these were used for histology and immunohistochemical stains or whole knee joints 
were processed for hard tissue embedding using Technovit 9100 New® as described 
below and these sections were used for TRAP and H&E staining. Each specimen was 
H&E stained to visualize the general morphology.   OA severity in the tibial plateau 
was evaluated according to a modified Mankin histological grading system [226] and 
a cartilage destruction score was assigned for each knee joint by three independent 
assessors. 
Histology tissue preparation – Hard tissue embedding and sectioning  
Technovit 9100 New® (Heraeus Kulzer GmbH, Germany) is a low temperature 
MMA embedding system used for non decalcified bone. The standard manufacturer 
guide was used to embed fixed samples. Briefly, fixed samples (4% PFA) were  
dehydrated in increasing concentrations of alcohol (70%, 80%, 90%, 100% - 3 days 
each concentration at 4C). Samples were defatted in xylene for 5 hours and pre-
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infiltrated for 5 days followed by infiltration for 5 days at 4C. Polymerization was 
performed by mixing polymerisation solutions made according to Technovit 9100 
New® brochure. EXAKT cutting and grinding system (Germany) was used to obtain 
sections of 60-90microns for staining and analysis.  
Bone marker injections: 
Figure 4-1,d-f shows calcein (10mg/kg, Sigma Aldrich) was injected intra 
peritoneally 6 weeks post-surgery (MSX-Medial Menisectomy).  Alizarin (20mg/kg, 
Sigma Aldrich) was also injected intraperitoneally 10 days after calcein. Rats were 
sacrificed at 8 weeks post surgery. 
Equilibrium Partitioning of an Ionic Contrast agent via microcomputed 
tomography (EPIC-microCT) 
Knee joints (after fixing in 4% paraformaldehyde) were soaked for 30 mins in an 
ionic contrast agent Hexabrix (40% Hexabrix/60% phosphate buffered saline 
solution). The severities of OA subchondral bone changes in MSX with its sham 
group were determined using a high resolution microCT scanner (μCT40, SCANCO 
Medical AG, Switzerland)  Femur and Tibia were scanned with isotropic voxel size 
of 16 μm (nominal resolution) in PBS as scanning medium. The x-ray tube voltage 
was 45 kV and the current was 177 μA, with a 0.5 mm aluminium filter. The 
integration time was 200 ms. The obtained images were segmented with an inbuilt 
software using constant thresholds to distinguish bone and cartilage. A circular area 
(0.004 cm2) of interest was selected in the middle of the load bearing subchondral 
bone areas. The selected area included only the subchondral bone plate and not the 
subchondral trabecular bone and growth plate tissue. A total of 30 consecutive 
tomographic slices were analysed. The meaningful subchondral bone plate 
measurements such as bone volume (mg HA/ccm) and BV/TV (%) were analysed 
using inbuilt software. Subchondral bone thickness was measured quantitatively 
using Axio Vision software by converting number of pixels to micro meters.   
Tartrate resistant acid phosphatase (TRAP) staining of paraffin embedded 
samples  
To detect osteoclast activity, TRAP staining was performed as described previously 
[225].  Paraffin sections of 5 μm thickness were deparaffinised in two changes of 
xylene (8 min each) and rehydrated (2 changes 95% ethanol, 2 min each; 1 change 
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70% and 50% ethanol each 5 min, deionised water 5 min). After rehydration, 
samples were placed in 0.2 M Acetate Buffer (0.2 M sodium acetate and 50 mM L(+) 
tartaric acid in ddH2O, pH 5.0) for 20 min at room temperature. Sections were then 
incubated with 0.5 mg/ml naphtol AS-MX phosphate (Sigma) and 1.1 mg/ml fast red 
TR salt (Sigma) in 0.2 M acetate buffer for 1-4 h at 37ºC until osteoclasts appeared 
bright red. Samples were counterstained with Haematoxylin, air dried and mounted 
with ProLong® Gold (Invitrogen) mounting solution. 
H&E staining 
Tissue slices were dewaxed in xylene and dehydrated in descending concentrations 
of ethanol (100% to 70%), and sections were then stained with Mayers’s 
haemotoxylin for 1-2 minutes before washing with tap water for 5 minutes. The 
slides were dehydrated in ascending concentration of ethanol (70% to 100%), stained 
with eosin for 15 seconds and cleared with xylene to be mounted on DePeX 
mounting medium (BDH Laboratory Supplies, England). 
Immunohistochemistry 
Immunohistochemistry was conducted using an indirect immunoperoxidase method. 
Tissue slices were dewaxed in xylene and rehydrated. Endogenous peroxidases were 
blocked by incubation in 0.3% peroxide for 30 min followed by repeated washing in 
PBS. The sections were then incubated with proteinases K (DAKO Multilink, CA, 
USA) for 20 min for antigen retrieval. The next step treated all sections with 0.1% 
bovine serum albumin (BSA) with 10% swine serum in PBS. Sections were then 
incubated with optimal dilution of primary antibody overnight at 4 °C ( Table 4-1). 
Optimum concentration of antibodies was determined using a series of dilutions.  
After 24 hours, sections were incubated with a biotinylated swine-anti-mouse, rabbit, 
goat antibody (DAKO Multilink, CA, USA) for 15 min, and then incubated with 
horseradish perioxidase-conjugated avidin-biotin complex for 15 min. Antibody 
complexes were visualized by adding buffered diaminobenzidine (DAB) substrate 
for 3 min and the reaction was stopped by rinsing sections in PBS. Sections were 
counterstained with Mayer’s haematoxylin for 10 sec each, and rinsed with running 
tap water. Following this, slides were dehydrated with ascending concentrations of 
ethanol solutions, cleared with xylene and mounted with a coverslip using DePeX 
mounting medium. Controls for the immunostaining procedures included conditions  
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where the primary antibody and the secondary (anti-mouse IgG) antibodies were 
omitted. An irrelevant antibody (anti CD-15), not present in the test sections, was 
used as an additional control. A list of antibody sources and dilutions used for this 
study are in Table 4-1. Meaningful parameters to describe area of interest were 
determined by measuring the thickness of the subchondral plate in all samples under 
10 x magnification and calculating the average length and calculating the average 
area. The percentage of positive staining cells in 3 fields of view per sample was 
counted to quantify.  
Table 4-1 A list of antibodies, sources and working dilutions used for immunohistochemistry 
 
Protein Dilution Source 
Sclerostin  1:100 Gift from Prof Jian Q Feng 
DMP-1  1:1000 Gift from Prof Jian Q Feng  
E11 
ab10288  1:250  Abcam 
DKK1 
ab109416  1:100 Abcam  
β-Catenin 
#9581  1:200 Cell Signaling 
AXIN-2 
ab107613  1:200  Abcam 
 
 
In situ cell death detection (apoptosis) using TUNEL 
Osteocyte apoptosis was assessed principally at a single cell level, based on labelling 
of DNA strand breaks (Terminal deoxynucleotidyl transferase dUTP nick end 
labelling or TUNEL technology) using In Situ Cell Death Detection Kit, Fluorescein  
(Roche, Germany) according to manufacturer’s protocol. Tissue sections were 
permeabilised for 30min at 37 °C with Proteinase K solution (Roche, Germany). As a 
positive control, sections were treated with DNase1 for 10 min at room temperature 
prior to the labelling procedure which was used to induce DNA strand breaks. The 
tunel reaction mixture / terminal transferace was omitted for the negative control. 
The subchondral bone plate was defined as starting from the calcified cartilage (CC) 
bone junction and ending at the marrow space. Meaningful parameters to describe 
our area of interest were determined by measuring the thickness of the subchondral 
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plate in all samples under 10 x magnifications and calculating the average length and 
calculating the average area. TUNEL positive osteocyte was counted in 3 fields per 
section within the defined area of interest using AxioVision Rel 4.8 Software. The 
average TUNEL positive osteocyte between control and OA are represented in a bar 
graph. 
Statistical analysis:  
Paired Student’s t-test  was used to determine any significance between control vs. 
OA subchondral bone, by counting the % positive staining cells in the field of view 
for immunohistochemistry, by counting the Avg OS.N and Avg OS.L (per unit area) 
for distribution studies, within the area of interest. * p ≤ 0.05 was considered 
significant.      
4.4 RESULTS 
Changes in gross morphology of the joints and disrupted osteocyte distribution 
in MSX 
Animals recovered quickly after surgery with no wound healing complications. 
Animal behaviour and weight was monitored and no significant differences were 
found between SHAM and MSX rats. All rats were initially assessed using H&E and 
micro-CT data. MSX showed high subchondral bone volume compared to SHAM 
control at 8 weeks post-surgery similar to human OA changes reported previously 
[225]. Figure 4-2 (a-b) shows representative images of safranin-o stained coronal 
sections of SHAM and MSX rat tibia, 8 weeks post surgery. Sham controls shows 
smooth cartilage surface with well-ordered cartilage zones. MSX group shows 
fibrillated articular cartilage and proteoglycan depletion compared to SHAM 
controls. Distribution of osteocytes is very evident in the subchondral bone. Red 
arrows represent osteocyte nucleus and yellow arrows represent empty osteocyte 
lacunae. Bar graph shows (Figure 4-2, c&d) average osteocyte lacunae (Avg.OS.Lac) 
density (p=0.001) and average osteocyte nucleus (Avg.OS.N) density (p=0.001) or 
viable osteocyte count, per unit area that was significantly increased in MSX group 
compared to SHAM controls. (Figure 4-2, e&f) shows representative SEM images of 
osteocytes from the subchondral area of MSX and SHAM. Osteocytes in the MSX 
group were disorganised with broken canalicular network compared to  
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well-organised and preserved canalicular network in SHAM controls.  These results 
show typical OA subchondral bone changes with hampered osteocyte distribution 
and morphology indicating drastic subchondral bone changes. 
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Figure 4-2 Disrupted osteocyte distribution and morphology 
 
(a-b and enlarged image) Safranin-O-stained images of rat tibia - 2 months post surgery, shows altered osteocyte distribution and proteoglycan depletion in the cartilage. (c-d) 
Average osteocyte nucleus and average osteocyte lacunae was increased in MSX group compared to Sham.; (e-f) SEM images showing disrupted osteocytes in the 
subchondral area of MSX compared to SHAM.   S: SHAM / Control group; M: MSX / OA group * statistically significant compared to S; *p ≤ 0.05; n=5.
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Altered micro-architectural and mineral properties of MSX subchondral bone 
compared to SHAM controls  
Equilibrium Partitioning of an Ionic Contrast agent via microcomputed 
tomography (EPIC-microCT) was used to non-destructively assess cartilage 
morphology and quantify the bone changes on the same sample. Figure 4-3, a&c 
shows representative 3-D reconstructions of coronal section and Figure 4-3, b&d 
shows axial view of sham and MSX tibia from EPICmicro-CT.  SHAM group shows 
preserved, smooth cartilage; subchondral bone has well-structured spaces and 
trabaculae. The Medial compartment of the MSX group shows subchondral cysts, 
fewer trabaculae with larger hollow spaces, osteophyte formation and increased bone 
remodelling rate compared to SHAM controls. Quantitative data indicate that there is 
a significant increase in the mineral content (Figure 4-3, e) and bone volume (Figure 
4-3, f) of the MSX group compared to SHAM controls. These results indicate altered 
subchondral bone remodelling and altered mineral metabolism.  
Macroscopic analysis of MSX and SHAM control joint 8 weeks post surgery. 
Figure4-4 (a&b) shows representative macroscopic, fluoro-stereomicroscope 
images of SHAM control and MSX tibia at 10 weeks post surgery. All rats with 
MSX surgery developed cartilage lesions and bone exposure in the medial 
compartment of the tibia.  Macroscopically the SHAM controls showed no cartilage 
damage in the medial and lateral tibial plateau. Significant calcein and alizarin label 
accumulation were detected along the margins and area of the medial compartment 
of the tibial plateau. The intensity (mean grey value) of the fluorescence was 
assessed in images captured using the same exposure time and magnification using 
image J  and MSX group shows, statistically significantly higher relative alizarin 
(p=0.0011) (Figure 4-4, c) and calcein (p=0.0074) (Figure 4-4, d) expression 
compared to SHAM controls that showed no such accumulation of fluorochrome 
lables. Figure 4-4, e&f are representative coronal sections (Hard tissue embedded 
and ground to 60μ thickness) showing progression of bone marker accumulation and 
suggests increased bone remodelling with increased net bone formation at both time 
points of injection and developing osteophyte.  
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Figure 4-3 : Altered micro-architectural and mineral properties in SHAM and MSX 
subchondral bone 
 
 (a&b)  shows representative 3-D reconstructions of coronal section and axial view of SHAM and 
MSX tibia (c&d) from EPICmicro-CT scans after incubating with the contrasting agent, Hexabrix. 
Quantitative shows mineral content (e) and bone volume (f). These results indicate significantly 
increased bone volume fraction and mineral content quantitative data in MSX group compared to 
SHAM group. S: SHAM / Control group; M: MSX / OA group * Statistically significant compared to 
S; *p ≤ 0.05. 
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Figure4-4 Macroscopic images and mineral distribution of the MSX and SHAM joint 8 weeks 
post surgery 
 
(a) Whole joint flurochrome images of SHAM group shows smooth, full thickness cartilage on the 
tibial join with no bone exposure. Whereas, (b) MSX/OA group shows cartilage lesions, bone 
exposure on the medial compartment, accumulation of calcein (green, injected at week 6) and alizarin 
(red, injected at week 8) along the margins of the tibial plateau. c&d shows progression of  bone 
marker accumulation in coronal sections and suggests increased bone remodelling with increased net 
bone formation and developing osteophyte at both time points. When quantified, e&f shows MSX 
group has significantly higher relative alizarin and calcein expression compared to SHAM. S: SHAM 
/ Control group; M: MSX / OA group * Statistically significant compared to S; *p ≤ 0.05; n=9.
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Dysregulated osteocyte markers in OA osteocytes 
Osteocytes selectively express sclerostin/SOST, which is  also characterised 
as a WNT antagonist. Comparative quantitative immunohistochemical analysis of 
SOST expression in the MSX group revealed that the percentage fraction of SOST-
positive osteocytes among total osteocytes in the subchondral bone is significantly 
less compared to SHAM controls (p=0.0022) (Figure 4-5, a-c). Conversely, osteocyte 
staining of Dentin Matrix Protein 1/ DMP1 characterised as a regulator of mineral 
metabolism, had significantly higher percentage of DMP1 positive osteocytes in the 
MSX group compared to SHAM controls (p=0.0078) (Figure 4-5, d-f). 
E11/Podoplanin an early osteocyte marker was significantly increased in MSX group 
compared to SHAM controls (p=0.001) (Figure 4-5, g-i). These results indicate 
dysregulated osteocyte phenotype and a possible reason for subchondral bone 
sclerosis and hampered mineral metabolism.  
Increased TUNEL and TRAP positive staining in MSX osteocyte  
Increased osteoclast activity accompanied by defective osteoclast is well 
documented in the pathophysiology of OA. Interestingly, (Figure 4-6, a-c)  TRAP 
(indicates bone resorption) stained MSX tibia sections showed significantly 
increased average number of TRAP positive osteocytes compared to SHAM controls 
(p=0.0001). TUNEL (indicates apoptosis) stained section (Figure 4-6, d-e) reveals 
that there are significantly more osteocytes undergoing apoptosis compared to 
SHAM controls. The average TUNEL positive osteocyte between MSX and SHAM 
control group are represented in a bar graph (p=0.0021) (Figure 4-6, f). These results 
indicate that osteocytes could play a role in directing osteoclastogenesis in OA 
subchondral bone.  
Disrupted WNT β-catenin signalling proteins in MSX subchondral bone 
osteocytes  
Osteocyte WNT β-catenin signalling is required for normal bone 
homeostasis. Quantitative immunohistochemical analysis revealed that MSX group 
showed significantly increased average percentage of (Figure 4-7, a-c) β-catenin 
(p=0.0075), and (Figure 4-7, d-f) AXIN 2 positive osteocytes (p=0.0089) in the MSX 
group compared to SHAM controls. Conversely, DKK1 (WNT antagonist) was 
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significantly decreased in the osteocytes of the MSX group compared to SHAM 
controls (p=0.001) (Figure 4-7, g-i).  
 
 
Figure 4-5 Dysregulated osteocyte markers 
 
Immunohistochemical analysis revealed that MSX group has a lower expression of (a-c) sclerostin 
positive (SOST: a negative bone regulator/WNT antagonist) osteocytes compared to SHAM. 
Conversely, the expression of (d-f) Dentin Matrix Protein 1 (DMP1: mineralization marker), (g-i) E11 
(early osteocyte marker) was significantly higher in MSX group compared to SHAM. S: SHAM / 
Control group; M: MSX / OA group * statistically significant compared to S; *p ≤ 0.05; n=4. 
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Figure 4-6 Defective osteoclast, osteocyte TRAP expression and increased apoptosis 
 
TRAP (indicates bone resorption) stained sections shows increased number of defective osteoclast and 
TRAP stained osteocytes in MSX group compared to SHAM (a-c) , A representative TUNEL stained 
section (d&e) shows that a significantly higher number of osteocytes were undergoing apoptosis in 
MSX group compared to SHAM. S: SHAM / Control group; M: MSX / OA group * Statistically 
significant compared to S; *p ≤ 0.05; n=5. 
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Figure 4-7 Dysregulated WNT β-catenin signalling proteins                                          
 
Immunohistochemical analysis revealed that the MSX group has higher expression of AXIN2 (a-c) 
and, β-catenin (d-f) compared to SHAM. Conversely, a lower expression of  (g-i) DKK1 positive 
(WNT antagonist) osteocytes were found in the subchondral bone area of the MSX group compared to 
SHAM. S: SHAM / Control group; M: MSX / OA group. * Statistically significant compared to S; *p 
≤ 0.05; n=4. 
 
4.5 DISCUSSION 
The pathology of OA is well established. However, its etiopathogenesis is 
widely debated and the subject of intense research. Bone and mineral changes have 
been well documented in OA but it is unknown if they precede or follow cartilage 
breakdown establishing a need for early intervention and better disease modifying 
therapeutic drugs [19, 227]. However, the study of early pathophysiological changes 
on human OA tissue is practically impossible as most tissues retrieved / collected 
from replacement surgeries are at the end-stage of OA. Therefore animal models are 
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critical in the study of disease progression and onset (or a time-point). This study, 
demonstrated that tibial subchondral architecture and remodelling closely mimics 
changes observed in human OA subchondral bone and osteocyte in a MSX rat model 
(8 weeks post surgery). This is the first study that characterises and associates the 
dynamic changes of mineral metabolism, osteocyte molecular markers and the 
involvement of WNT β-catenin signalling pathway in OA development. 
Bone research has largely focused and targeted on the fuctions of osteoblasts 
and osteoclasts and it is now evident that they are altered in OA [3]. Recent in vitro 
and in vivo bone studies have emphasised various roles for osteocytes in physiology 
and pathology; in OA subchondral bone sclerosis is a recognised manifestation. The 
findings from this report support the data from previous in vivo minesectomy studies, 
demonstrated that the subchondral plate thickness was significantly increased in the 
MSX model compared to SHAM [216, 218]. Fluorochrome labelling at different 
time points and EPICmicroCT data demonstrated that mineral content in the medial 
compartment significantly increased compared to SHAM. When closely observed, 
there is an uneven distribution of mineral content with very high or very low mineral 
distribution compared with SHAM.  
 Osteocytes play an important functional role in regulation of mineralization 
via the expression of Dentin Matrix Protein-1(DMP1). Disrupted expression of this 
protein leads to defective osteocyte maturation [201, 228]. In our study, consistent 
with the increased expression of DMP1 in OA human samples, we observed 
significantly increased expression of DMP1. The subsequent increase in E11 (early 
osteocyte marker [185]) was significantly increased indicating OA bone has 
hampered mineral metabolism with woven bone like phenotype. Decreased osteocyte 
expression of SOST (Negative bone regulator/ WNT inhibitor/ BMP inhibitor) in OA 
human samples has been well established and associated with increased bone 
formation [87, 180]. Results from the study conducted here infer that osteocytes are 
not maturing to produce sufficient SOST to maintain bone homeostasis. 
Roux in 1881 suggested that bone has the capacity to adapt to mechanical 
loading by altering its architecture when bone cells regulate themselves as a result of 
local regulation of osteocytes and influenced by mechanical stimuli [229]. Based on 
this model, it can be confirmed that the increased osteocyte number per unit area, 
observed in the studied MSX group, can be attributed to the increased subchondral 
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bone volume. Another study conducted by Hernandez et al on osteocyte density 
suggests that woven bone has more osteocyte numbers and hence  may undergo 
remodelling at an accelerated rate compared to cortical bone [230]. Further, 
considering that there is sufficient evidence supporting that osteocytes are local 
initiators of bone formation/bone remodelling [13] and the MSX model has been 
mechanically destabilised, to interpret that the increased subchondral bone with 
hampered mineral content (osteoid phenotype) could be the result of an increased 
osteocyte number per unit area.  
  Osteocyte apoptosis and the role of osteocyte in OA osteoclastogenesis or 
bone resorption has been emphasised in independent studies [183, 231]. The findings 
observed here makes it reasonable to suspect that osteocyte death (TUNEL positive 
osteocyte) followed by increased bone remodelling (More bone formation and also 
TRAP positive osteoclast and osteocytes indicate more bone resorption) as a 
mechanism to heal the bone. Although TRAP positive osteocytes and their functions 
have been debated, few studies have shown and evaluated TRAP positive osteocytes 
close to the resorbing surface [232, 233]. Owing to the fact that human OA samples 
had more TRAP positive osteocytes compared to the controls [225] and recapturing 
this in our study reinstates that TRAP positive osteocytes could control the direction 
of osteoclast resorption in OA.  Together we can say that in OA there is a question of 
balance in bone remodelling where there is increased focal bone remodelling with 
net bone formation with hampered mineral metabolism.  
   There is a body of knowledge in WNT β-catenin signalling pathway and an 
enormous evidence of the active role of this pathway in OA. However, no targeted 
approach for therapy has been elucidated [176-178]. This led us to investigate the 
role of this pathway in OA osteocyte to gain a novel mechanistic insight for the OA 
osteocyte pathophysiobiology. It is now evident that osteocyte β-catenin signalling 
specifically is required for normal bone homeostasis [29, 179].  Molecular response 
of articular cartilage to mechanical injury down regulates  β-cateninin joints [27, 
181]. Previous studies have shown that WNT β-catenin signalling is activated as a 
result of mechanical loading on osteocytes and that they are major signalling 
pathway for mechanotransduction [29]. This pathway has also been implicated in 
osteocyte survival and that osteocyte apoptosis correlates with the increased 
osteoclast recruitment and bone resorption [182, 183].  
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Like SOST, DKK1 is a soluble inhibitor and a master regulator of WNT 
signalling pathway playing a balancing role where increased expression is associated 
with bone resorption and decreased expression is associated with bone formation. Its 
role and levels of expression in OA has been debated [173]. Increased expression of 
Plasma and synovial DKK1 was reported and their levels were inversely correlated 
with the radiographic severity with knee OA patients [174]. The protective and 
deleterious roles of DKK1 and its association with tissue expression is not 
known[154].  Our study reveals that MSX rat model has a significantly decreased 
expression of WNT inhibitors DKK1 and SOST that promotes WNTs and receptor-
ligand binding and stabilises the expression of phosphorylated  β-cateninand further 
translocated into the nucleus and increases the expression of target gene AXIN2.  
Although activation or deactivation of signalling molecules controlling 
osteocytes promise to hold great potential to be  high priority targets for novel 
therapies, exploration of the biological relevance of decreased osteocyte expression 
of DKK1 and SOST in OA is needed before any definite putative conclusions are 
drawn. Possibilities that WNT β-catenin pathway could interact with other major 
pathways dependently or independently to maintain joint homeostasis.  
Together with the current knowledge, this cascade of events in osteocytes and 
osteocyte WNT β-catenin signalling pathway could play a major role in the 
pathogenesis of OA and could be a possible reason for the focal increased bone 
formation, which is followed by deposition of osteoid type of bone due to the 
disturbed maturation of osteocytes.   
4.6 CONCLUSION 
OA MSX experimental rat model resembles the human situation closely 
showing similar changes in subchondral bone and osteocyte phenotype. 
Investigations in this model showed dynamic changes of mineral metabolism in 
subchondral bone plate that may be related to the hampered osteocyte WNT β-
catenin signalling pathway. Osteocytes and their signalling molecules should, 
therefore, be a high priority target to unveil the potential mechanism of OA 
pathophysiology and for development of potential therapies for OA. 
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5.1 ABSTRACT 
Introduction: Proinflammatory cytokines are believed to play a pivotal role in the 
initiation and development of osteoarthritis (OA) [22]. It has been proposed that OA 
may be driven by low-grade inflammatory processes associated with subchondral 
bone sclerosis [234]. Tumor Necrosis Factor α (TNFα) is implicated in the 
pathophysiology of OA and is associated with bone loss and down regulation of the 
WNT β-catenin pathway in osteoblasts [235]. However, effect of TNFα on 
osteocytes, which constitute 90% of all bone cells, is unknown. The aim of this study 
was to evaluate the molecular regulation of osteogenesis by osteocytes and evaluate 
the synergistic effect of osteocytes with osteoblasts under the influence of low-dose 
inflammation (TNFα). This study also tests the role of the osteocyte-WNT β-catenin 
signalling pathway in these phenomena. 
Methods: To test the effect of osteocytes on osteogenesis in an inflammatory 
environment, MLOY4 cells (an osteocyte cell line) were cultured under the influence 
of low (0.5ng/ml) and high (40ng/ml) doses of TNFα. Soluble factors from low-dose 
and high-dose stimulated osteocyte groups were used to culture primary osteoblasts 
for 7 days. ALP activity, calcium deposition, the gene expression of ALP, OPN, 
COL1 and RUNX2 were used to determine the osteogenic potential in each of the 
experimental groups. Gene and protein expression of the osteocyte-WNT β-catenin 
signalling pathway (CTNNB1, AXIN2 and DKK1) was monitered in co-culture 
experiments.  
Results: MLOY4 cells treated with high-dose TNFα demonstrated decreased 
osteogenic differentiation. In contrast, MLOY4 treated with low-dose TNFα 
demonstrated increased proliferation and osteogenic potential. Further, when  soluble 
factors from MLOY4 cells after 3-day low-dose TNF treatment were used to culture 
primary osteoblasts. Synergistic effect on osteogenesis was demonstrated in a dose 
and time dependent manner, showing both increase in osteogenic differentiation 
markers and an upregulation of the WNT β-catenin pathway along with a down 
regulation of DKK1 compared to controls. The opposite was found in high dose.  
Conclusion: These results indicated a differential regulation of osteocytes under the 
influence of a low and high-dose of an inflammatory cytokine (TNFα). Low-dose, 
long-term inflammation creates a pro-osteogenic niche that potentially modulates the 
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activities of osteocytes and osteoblasts leading to the activation of the WNT β-
catenin pathway and promoting bone formation. The results of this study indicate 
that osteocytes could potentially play a role in subchondral bone sclerosis via the 
WNT β-catenin pathway, preconditioned with low-dose long-term inflammatory 
mediators.  
5.2 INTRODUCTION 
The pathogenesis and aetiology of OA is dynamic, complex and unclear with 
currently no treatments that prevent or slow the progression of the disease. It is now 
accepted that OA is a disease of the entire joint and changes observed in OA are due 
to a combination of factors that range from mechanical to biochemical [19]. OA is 
characterised pathologically by focal areas of cartilage damage and subchondral bone 
changes and it has been proposed that the disease process is associated with low-
grade inflammation [4, 137, 236]. Although low-grade inflammation is detected in 
OA, it is viewed as a secondary phenomenon related to the destruction of cartilage 
[25].  
An increased number of migratory inflammatory cells and the substances 
secreted by these cells have been recognised in OA joint tissues [18], leading to 
speculation that inflammation may play a major role in OA. Inflammation induced 
pathologic bone loss in diseases like RA is well established. This is characterised by 
the activation of bone resorption and the inhibition of bone formation associated with 
alterations in the WNT signalling pathway, which is an anabolic pathway that 
induces maturation and differentiation of osteoblasts [237].  
TNFα is a major proinflammatory cytokine that has been shown to suppress 
osteoblast maturation in vitro by inhibiting RUNX2 [238]. This in turn, suppresses 
its target genes ALP and COL-1 resulting in impaired bone matrix deposition and 
mineralization. Increasing evidence indicates that TNFα has an important role in not 
only in inflammatory arthritis like RA, but also in degenerative joint diseases like 
OA [4]. However, the subchondral bone changes between OA and RA are opposite 
with increased bone volume in OA and bone resorption in RA. Even though anti-
TNFα therapy has shown some promising results in the treatment of OA; its 
mechanisms of action and its specific role in OA treatment remains unexplored and 
heavily debated [5, 239, 240]. Although stimulatory effects of TNFα on osteogenesis 
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have been well characterised, the dose and time dependent effects on osteocytes have 
not been studied until now. 
The aim of this study was to evaluate dose and time dependent effects of TNFα 
on osteocytes and the synergistic effect of osteocytes and osteoblasts on osteogenesis 
(potential to form bone) via the WNT β-catenin pathway. 
5.3 MATERIALS AND METHODS 
MLOY4 is a well characterized and established osteocyte cell line derived from 
mouse long bones (Kindly provided by Prof. Lynda F Bonewald, University of 
Missouri, Kansas City, Texas). These cells were seeded at a density of 2 × 104 
cells/well on collagen coated  24 well tissue culture plates (BD Falcon, North Ryde, 
NSW, Australia) and  cultured in α-minimum essential media (α-MEM), 
supplemented with: 5% heat-inactivated fetal bovine serum (HI-FBS, Hyclone); 5% 
heat-inactivated calf serum (HI-CS, Hyclone); 1.2 μg/ml Fungizone (Gibco); 60 
μg/ml penicillin (Gibco); and Streptomycin (Gibco) at 37°C and 5% CO2  in air. 
Osteoblasts were established from redundant tibial bone obtained following knee 
replacement surgery (relatively healthy side was chosen to isolate cells) after 
informed consent was given by the patients [225]. These cells were seeded at a 
density of 2 × 104 cells/well on 24 well tissue culture plates (BD Falcon, North Ryde, 
NSW, Australia) and  cultured in α-minimum essential media (α-MEM) 
supplemented with; 10% fetal bovine serum; 1.2 μg/ml Fungizone (Gibco); 60 μg/ml 
penicillin (Gibco); and Streptomycin (Gibco) at 37°C and 5% CO2  in air. 
Osteoblasts and MLOY4 cells were treated with pro-inflammatory cytokine, 
recombinant human Tumor Necrosis Factor-α (TNFα, dilution range – 0.05ng/ml-
100ng/ml) purchased from Gibco® (Life Technologies - Applied Biosystems, 
Mulgrave, VIC, Australia) for 14 days. Following initial dose dependance 
experiments, 0.5 ng/ml was chosen as low-dose and 40 ng/ml as high-dose.  
Osteocyte media without any cytokine supplementation was used as control. 
Conditioned media experiments 
On day 3, serum free osteocyte media with TNFα was added to MLOY4 cells. After 
24 hours, this media was collected and mixed with fresh media (at a ratio of 2:1) to 
make the conditioned media. This conditioned media was then used to culture 
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primary human osteoblasts. Osteoblast cultures without any cytokine 
supplementation was used as ‘control’. ‘Normal’ was assigned to the conditioned 
media made from control sample. 
Alkaline phosphatase (ALP) activity  
Intracellular ALP activity was determined with the Quantichrom™ Alkaline 
Phosphatase Assay Kit (Gentaur Belgium BVBA, Kampenhout, Belgium), a p-
nitrophenyl phosphate (pNP-PO4) based assay. Osteoblastic cells were rinsed twice 
with PBS, and lysed in 200µl of 0.2% Triton X-100 in MilliQ water, followed by 20 
minutes agitation at room temperature. A 50µl sample was then mixed with a 100μl 
working solution and absorbance was measured after 5 minutes at 405nm in a 
microplate reader. 
Calcium assay 
Calcium was extracted by incubating the samples in 0.6N hydrochloric acid 
overnight and subsequently quantified using the QuantichromeTM Calcium Assay kit 
(Gentaur Belgium BVBA, Kampenhout, Belgium) according to the manufacturer’s 
protocol [241]. The absorbance was measured at 612nm. 
MTT assay 
Metabolic activity was assessed by MTT assay using the methods as described 
previously [242]. Briefly, 0.5 mg/ml of MTT solution (Sigma-Aldrich) was added to 
each well and incubated 37°C to form formazan crystals. The culture media was 
removed and the formazan was solubilised with dimethyl sulfoxide (DMSO) after 4 
hours. The absorbance of the formazan-DMSO solution was read at 495 nm using a 
plate reader. All results were demonstrated as the optical density values minus the 
absorbance of blank wells. 
RNA isolation 
Cells were washed with PBS and lysed using QIAzol lysis reagent (Qiagen Pty Ltd, 
Doncaster, VIC, Australia). Total RNA was isolated as described previously [225]. 
RNA concentrations were assessed using a Nanodrop spectrometer (Thermo 
Scientific, Scoresby, Vic., Australia).  
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Quantitative real-time PCR 
cDNA was prepared from 500ng RNA templates by reverse transcription using 
DyNAmoTM cDNA Synthesis Kit (Finnzymes Oy., Vantaa, Finland) according to the 
manufacturer’s protocol. The mRNA expression of ALP, RUNX2, DMP1, E11, 
RANKL and COL1 was assessed. The mRNA expression of key genes of the WNT 
β-catenin signalling pathway, β-catenin, AXIN2 and DKK1 was also assessed. 
Primers were obtained from GeneWorks Pty Ltd (Hindmarsh, SA, Australia) and are 
summarized in Table 5-1.  Quantitative real time PCR (qPCR) reactions were 
performed using the ABI Prism 7000 Sequence Detection System (Applied 
Biosystems). The system enables direct detection of PCR products by measuring the 
increase in fluorescence caused by the binding of SYBR Green dye to double-
stranded  DNA. The reactions were incubated at 95°C for 10 minutes; and then 95°C 
for 15 seconds and 60 °C for 1 minute for 40 cycles. PCR reactions were validated 
by observing the presence of a single peak in the dissociation curve analysis. The 
housekeeping gene glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was used 
as an endogenous reference gene for analysis using the Comparative Ct (Cycle of 
threshold) value method. 
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Table 5-1 Human and mouse specific primer sequences used for real-time PCR analysis of gene 
expression 
 
Mouse specific primers used in this study 
Gene name Forward primer (sequence 5’-3’) Reverse primer (sequence 5’-3’) 
ALP ATCTTTGGTCTGGCTCCCATG TTTCCCGTTCACCGTCCAC 
OPN CAATGAAAGCCATGACCACATGG CTCATCTGTGGCATCAGGATACTG 
COL1 AGAACAGCGTGGCCTACATG TCCGGTGTGACTCGTGC 
RUNX2 GACTGTGGTTACCGTCATGGC ACTTGGTTTTTCATAACAGCGGA 
DMP1 AGATCCCTCTTCGAGAACTTCGCT TTCTGATGACTCACTGTTCGTGGGTG 
DKK1 AATCTGCCTGGCTTGCCGAA GTGGAGCCTGGAAGAATTGC 
β-catenin TGCTGAAGGTGCTGTCTGTC CATCCCTTCCTGCTTAGTCGC 
Axin 2 TCAGGTCCTTCAAGAGAAGCG ACTGCGATGCATCTCTCTCTG 
β actin CATACCCAAGAAGGAAGGCTGG TGAGATGGGTCAGGGTTTAGC- 
Human specific primers used in this study 
ALP ATCTTTGGTCTGGCCCCCATG AGTCCACCATGGAGACATTCTCTC 
OPN TCACCAGTCTGATGAGTCTCACCATTC TAGCATCAGGGTACTGGATGTCAGGTC 
COL1 AGAACAGCGTGGCCTACATG TCCGGTGTGACTCGTGC 
RUNX2 GACGAGGCAAGAGTTTCACC ATGAAATGCTTGGGAACTGC 
DKKI TCCGAGGAGAAATTGAGGAA CACAGTCTGATGACCGGAGA 
β-catenin GGTGCTATCTGTCTGCTCTAGT GACGTTGACTTGGATCTGTCAGG 
Axin 2 GCAGACGACGAAGCATGTC GCCTTTCCCATTGCGTTTGG 
GAPDH TCAGCAATGCCTCCTGCAC TCTGGGTGGCAGTGATGGC 
 
 
Western Blotting 
To assess for the activation of the WNT  pathways , cells were first washed with cold 
PBS and then lysed with Hepes-Triton protein lysis buffer (20 mM Hepes, 2mM 
EGTA, 1% Triton X-100, 10% Glycerol, pH=7.4). The lysis buffer was 
supplemented with appropriate dilutions of protease inhibitor (cOmplete ULTRA 
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Tablets, Mini, EDTA-free, EASYpack - Roche Diagnostics Australia Pty Limited, 
Castle Hill, NSW, Australia) and phosphatase inhibitors (PhosSTOP Phosphatase 
Inhibitor Cocktail Tablets - Roche Diagnostics Australia Pty Limited, Castle Hill, 
NSW, Australia). The total protein concentration was calculated by performing a 
BCA Protein Assay Reagent (bicinchoninic acid) (Thermo Scientific Pierce Protein 
Biology Products, Rockford, Illinois, USA). The protein samples were fractionated 
by gel electrophoresis in 10% polyacrylamide gels under reducing conditions and 
were transferred to nitrocellulose membranes. The membranes were blocked with 5% 
bovine serum albumin (BSA) and probed with primary antibodies overnight at 4 °C. 
The next day the blots were washed with Tris Buffered Saline-Tween (TBST) then 
probed with their appropriate secondary antibodies. The blots were again washed 
(three times) with TBST and then imaged using enhanced chemiluminescence 
(ECL). Antibodies used for this technique are listed in Table 5-2. 
Table 5-2 A list of antibodies, sources and working dilutions used for western blotting 
 
Protein Dilution Source 
DKK1 
Ab109416 
 
1:1000 Abcam 
β-catenin 
#9581 
 
1:1000 Cell Signaling 
AXIN-2 
Ab107613 
 
1:3000 Abcam 
GAPDH 
SC-32233 
 
1:2000 Santa Cruz 
 
Statistical analysis 
The relative levels of expression of mRNAs were compared between control and the 
treated groups using Student’s t test. The DCT value was obtained by subtracting the 
average Ct value of the endogenous references selected from the test mRNA Ct value 
of the same samples. The DDCT was determined by subtracting the DCT of the 
control sample from the DCT of the target sample. The relative mRNA quantification 
of the target gene was calculated by 2_DDCT.  A value of p < 0.05 was considered 
significant. Error Bars are SD. 
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5.4 RESULTS 
Differential regulation of ALP activity on osteocytes and osteoblasts by TNFα.   
Figure 5-1 shows ALP activity. Figure 5-1a shows that TNFα inhibit ALP 
activity in osteoblasts in a dose dependent manner at all time points except day 1. 
Figure 5-1b shows TNFα on osteocytes promoting ALP activity at lower doses of 
0.25ng/ml and 0.5ng/ml at every time point compared to its control; at higher-doses 
TNFα inhibited ALP activity. At every time point, 0.5ng/ml of TNFα on osteocytes 
increased ALP activity significantly compared to 40ng/ml. Based on this differential 
regulation on osteocytes, for further experiments, 0.5ng/ml of TNFα was chosen as 
low-dose and 40ng/ml of TNFα as high-dose.  
 
Figure 5-1 Effect of TNFα on ALP activity of osteocytes/MLOY4 and osteoblast 
 
(a) Shows dose (range 0-100ng/ml) dependent effect on Day 1, 3, 7, 14 of TNFα on osteoblasts. (b) 
Shows dose (range 0-100ng/ml) dependent effect on Day 1, 3, 7, 14 of TNFα on osteocytes. Y axis: 
nmoles/min/μg protein represented as fold change to its own day control.* Statistically significant 
 116 Chapter 5 Role of osteocyte-WNT β-catenin pathway in long-term, low-dose inflammation and its potential 
pathological role in osteoarthritis 
compared to its control, p<0.05. o 40ng/ml dose is statistically significant compared to 0.5ng/ml dose 
of TNF α, p<0.05.  
 
Effects of TNFα on osteogenesis in osteocytes  
ALP Activity, MTT proliferation assay and Gene expression 
The osteogenic potential was tested at the following time points: day 1, day 3 
and day 7. Figure 5-2a shows intracellular ALP activity significantly increasing with 
low-dose stimulation of TNFα in osteocytes, whereas opposite effects were observed 
with higher doses. MTT proliferation assay in Figure 5-2b shows that there was 
increased proliferation of MLOY4 cells stimulated with high and low-dose TNFα at 
day 3 with no statistical difference. At day7 with the low-dose of TNFα stimulation, 
proliferation was significantly reduced compared to the high-dose and control. Gene 
expression data was mixed and for details refer Figure 5-2 c&d.  Briefly, at low-dose, 
bone markers ALP, OPN, RUNX2, COL-1 was significantly increased or showed an 
increasing trend at every time point compared to its controls. At high-dose these 
bone marker genes were significantly decreased or showed a decreasing trend at 
every time point. Osteocyte media without any cytokine supplementation was used 
as control. This data implies that high and low dose of TNFα have the potential to 
affect osteocytes differently and specifically, osteocytes have opposite effects on 
osteogenesis/ potential to form bone to low and high doses of TNFα. 
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Figure 5-2 Dose and time dependent effects 
of TNFα on osteogenesis by osteocytes  
 
(a) Effect of TNFα on intracellular ALP 
activity of MLOY4/osteocyte cells 
represented as relative expression of 
nmoles/min/μg protein (b) MTT assay. 
(Effect of TNFα on proliferation of 
MLOY4/osteocyte cells) (c) Gene expression 
data of (c, i-v) ALP,  COL1, OPN, DMP1 
and RUNX2 respectively on stimulation with 
low-dose TNFα on MLOY4/osteocytes. (d) 
Gene expression data of (d, i-v) ALP,  COL1, 
OPN, DMP1 and RUNX2 on stimulation 
with high-dose TNFα on MLOY4/osteocytes 
Y axis: relative gene expression normalised 
to β-actin represented as fold change to its 
controls; * Statistically significant compared 
to its control, p<0.05. 
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Effect of preconditioned (TNFα) osteocytes on osteogenic differentiation of 
osteoblasts 
ALP Activity, Calcium assay, MTT proliferation assay and Gene expression 
Figure 5-3a shows intracellular ALP activity significantly increased when 
soluble factors from low-dose TNFα stimulated osteocytes were used to culture 
osteoblasts compared to high, normal and control groups. The largest difference was 
found when we compared day 7 low-dose group with Day 7 high-dose group. 
Calcium deposition shown in Figure 5-3b followed a similar trend as seen in 
intracellular ALP activity. MTT assay in Figure 5-3c showed increasing in 
proliferation trend from day 1 to day 7 in all groups. Gene expression in Figure 5-3d 
presenting data from low-dose TNFα stimulated osteocytes on osteoblasts reveals 
that bone markers ALP, OPN, RUNX2 and COL-1 were significantly increased in a 
time dependent manner compared to control and normal groups. At high-dose these 
bone marker genes were significantly decreased or showed a decresing trend in a 
dose and time dependent manner. Also, at every time point, gene expression was 
significantly increased in low-dose group compared to high dose group. Osteoblast 
media without any cytokine supplementation was used as ‘control’. ‘Normal’ was 
assigned to the conditioned media made from control sample. This data implies a 
functional relationship between osteocytes and osteoblasts suggesting a 
synergistically stronger influence on osteogenesis. 
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Figure 5-3 Conditioned media experiments: 
Effect of preconditioned (TNFα) osteocytes 
on osteogenic differentiation of osteoblasts.  
 
(a) Intracellular ALP activity relative 
expression of nmoles/min/μg protein. (b) 
Calcium assay represented as calcium in 
mg/mg protein (c) MTT/proliferation assay (d) 
Gene expression data  of  (d, i-iv) ALP, 
RUNX2, COL1, OPN respectively. 
Y axis: relative gene expression normalised to 
GAPDH,  represented as fold change to Day1 
control group;  
Control: Osteoblast media without any 
cytokine supplementation.  
Normal: conditioned media made from 
control sample. 
* Statistically significant compared to its 
control within each time point (grey bars), p 
<0.05. 
o Statistically significant compared to low-
dose of TNF α, p<0.05.  
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TNFα dose and time dependent regulation of the WNT β-catenin signalling 
pathway  
Gene and protein expression 
Gene expression data in Figure 5-4a reveals that at low-dose stimulation of 
TNFα on osteocytes activated the osteocyte-WNT β-catenin signalling pathway with 
significantly increased expression of β-catenin, AXIN 2 (target gene) and decreased 
expression of the negative regulator of the WNT β-catenin signalling pathway 
(DKK1), compared to its controls. However, in higher doses an inhibition of WNT β-
catenin signalling pathway was observed.  
The synergistic effect of osteocytes and osteoblasts in the co-culture 
experiments produced a stronger response to activate the WNT β-catenin signalling 
pathway  when low-dose TNFα stimulated osteocytes were used to culture 
osteoblasts compared to high, normal and control groups. Figure 5-4b shows a 
significantly increased expression of β-catenin, AXIN2 (target gene) and a decreased 
expression of DKK1 (negative regulator of WNT β-signalling pathway). Inhibition of 
the WNT β signalling pathway was observed in the higher dose group compared to 
normal and control groups. Similar trend was observed at the protein level as shown 
in figure 5-4d.  
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Figure 5-4 TNFα dose and time 
dependent regulation of the WNT β 
signalling pathway  
 
(a) Effect of low-dose TNFα on 
MLOY4/osteocytes (a, i-iii) Gene 
expression of DKK1, β-catenin, AXIN2 
respectively (b) Effect of high-dose 
TNFα on MLOY4/osteocytes (b, i-iii) 
Gene expression of DKK1, β-catenin, 
AXIN2 respectively.  For a & b, relative 
gene expression normalised to β-actin 
represented as fold change to its controls. 
(c, i-iii) Gene expression data from 
condition media experiments of DKK1, 
β-catenin, AXIN2 respectively. Relative 
gene expression normalised to GAPDH 
represented as fold change to D1 control. 
* Statistically significant compared to its 
control, p <0.05. o Statistically 
significant compared to low- dose of 
TNF α, p<0.05. (d) Western blot 
showing protein expression of DKK1, β-
catenin, AXIN2. 
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5.5 DISCUSSION 
Pathologic bone loss or gain is characterised by an imbalance in the bone 
(re)modelling process that is tightly regulated and highly complex. In contrast to  
classical “inflammatory” joint diseases like Rheumatoid Arthritis (RA), that lead to 
bone resorption/bone erosion [172], degenerative joint diseases like OA are 
characterised by “low-grade” inflammation and new bone formation. However, both 
of these diseases lead to a destruction of the joint architecture. 
Synovial inflammation (synovitis) has been reflected in many of the signs and 
symptoms of OA including joint swelling, effusion, stiffness and redness [243]. This 
synovitis is cytokine-driven and there is evidence to suggest that OA chondrocytes 
and synovial cells produce cytokines and have receptors to respond to cytokines 
[134]. In OA, vascular penetration from the subchondral bone to the cartilage is 
evident with an increased expression of inflammatory cytokines in the subchondral 
bone [244]. These bone-derived cytokines are believed to diffuse into the cartilage 
through fissures at the osteochondral junction [4]. Osteoblasts and osteoclasts are 
proven to dysregulate bone (re)modelling in an inflammatory setting in OA [186, 
245]. All these factors and tissues are closely linked with complex functional 
interactions that impact the entire joint, perpetuating a vicious cycle.  
Matzelle M et al demonstrated enhanced bone formation in a declining 
inflammatory environment conducted in a serum transfer model of arthritis that led 
to the repair of focal bone loss with the activation of  the WNT β signalling pathway 
[238]. This observation demonstrated that inflammation impairs the ability of 
osteoblasts to form bone and that lowering the level of inflammation led to bone 
formation. However, the role of osteocytes in inflammation is not elucidated. 
Furthermore, Birmingham et al in their novel in vitro 3D co-culture and conditioned 
media experiments demonstrated that factors from osteocytes and osteoblasts 
produce a stronger response to MSCs to maintain bone homeostasis [246]. Our study 
reports the impact (dose and duration) of proinflammatory cytokine (TNFα) on 
osteocytes and its synergistic effect with osteoblasts on osteogenesis in vitro.  
MLOY4 cells are a well characterised osteocyte cell line [84, 106] and have 
been used in this study. Although cytokines (TNFα) are known to be osteoinhibitory 
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in large doses [143], immunological responses (low-dose inflammation) and 
inflammatory modulators are known to be of prime importance in bone healing and 
repair after a fracture, and their mechanisms have been implicated in bone 
(re)modelling [247].Our study is consistent with this finding implying an anabolic 
effect of TNFα. 
Gerstenfeld, et. al, in two separate models of bone repair, demonstrated 
impaired intramembranous bone formation during bone repair in the absence of 
TNFα [248]. In our study, osteoblasts inhibited osteogenesis in a dose and time 
dependent manner that is in agreement with previous reports [249]. We demonstrated 
that osteocytes/MLOY4 cells exposed to low-dose long-term inflammation promoted 
osteogenesis in vitro, whereas high-doses of TNFα inhibited the bone forming 
potential of these cells. The bone forming potential of the cells (osteocytes and 
osteoblasts) was confirmed by enhanced intracellular ALP activity and the 
expression of a panel of genes (ALP, OPN, RUNX2) that have been implicated as 
determinants of osteogenesis. 
 We also show that osteoblasts stimulated with conditioned media from low-
dose TNFα stimulated osteocytes promoted the osteogenic potential, whereas the 
inverse (high-dose) promoted bone resorption potential, suggesting a synergistically 
stronger influence. This is in line with Birmingham, et. al [246]. It is possible that 
with lower and longer term doses of inflammation, osteocytes and osteoblasts may 
promote osteogenesis. TNFα (at lower doses) and other proinflammatory molecules, 
and their signaling networks, may prepare the niche through osteocytes for the 
initiation of an osteogenic response leading to subchondral bone sclerosis as 
observed in OA. Effects of TNFα are concentration, time and cell type dependent, 
which dictates their metabolic (anabolic or catabolic) outcomes, making TNFα 
therapy in OA patients a debatable clinical modality.  
Osteocytes play an important functional role via Dentin Matrix Protein-1(DMP1) in 
normal postnatal chondrogenesis and subsequent osteogenesis. Disrupted expression 
of this protein leads to defective osteocyte maturation [201, 228, 250]. Consistent 
with the increased expression of DMP1 in OA human samples (Chapter 3), this study 
observed significantly increased expression of DMP1 in osteocytes with low-dose 
TNFα, whereas higher doses of TNFα inhibited the expression of DMP1. With this in 
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mind, in OA perspective, hyperactivation of DMP1 may potentially hamper 
osteocyte maturation and mineral deposition in the subchondral bone. This could 
further have a role in chondrocyte hypertrophy resulting in  cartilage degeneration 
and increase the osteogenic activity of osteoblasts, causing OA subchondral bone 
thickening or subchondral bone sclerosis. 
Fully differentiated cells maintain their specialised character through signalling 
pathways. Amongst these signalling factors, secreted proteins from WNT β-catenin 
pathways are reported to regulate many critical fundamental biological factors [26].  
The role of the WNTs in bone formation and (re)modelling has been reviewed over 
the last half decade and its role in OA has been emphasised [27]. More recently, the 
osteocyte-WNT β-catenin pathway has been shown to be  a major signalling pathway 
required for mechanotransduction in bone in vivo [28]. This pathway is also critical 
for normal bone homeostasis [29]. Given the importance of the WNT β-catenin 
pathway in cartilage and bone biology, specifically its importance in osteocyte 
biology and inflammatory arthritis, this study investigated whether this pathway 
would play a role in the osteocyte OA pathophysiology. DKK1 (an inhibitor and the 
master regulator of the WNT β-catenin signalling pathway), is known to prevent 
osteophyte formation by neutralising anabolic repair mechanisms and supporting 
catabolic pathways of joint destruction [251]. Diarra et al [172] shows evidence that 
the WNT β-catenin signalling pathway, through DKK1 can determine alternative 
phenotypes of RA and/or OA-like bone remodelling in the joint repair of 
inflammatory arthritis.  DKK1 is known to play a key role in controlling not only 
osteoblasts but also osteocytes [172].  In addition, TNFα could indirectly stimulate 
DKK1 production via a mechanism that is to date unexplored  [252].  This study has 
shown that the WNT β-catenin signalling pathway was activated via DKK1 in low-
dose inflammation and in high doses of TNFα the expression of DKK1 was 
inhibited. The activation of the WNT β-signalling pathway was demonstrated by the 
increased gene expression of β-catenin (the read out for WNT signalling pathway), 
AXIN2 (target gene in the WNT signalling pathway), and decreased expression of 
DKK1.  
This study suggests that inflammation, osteodifferentiation and 
osteoproliferation are related, and that inflammation triggered by unknown stimuli  
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(e.g. mechanical stress or injury) drives a bone anabolic process in which the WNT 
β-catenin pathway and down regulation of DKK1 play a prominent role. Moreover, 
the changes seen in OA are site-specific without any clear explanation. Given that 
osteocytes are dendritic, infers a potential to communicate with each other at 
preferred distances. This could explain inflammation induced site-specific 
(re)modelling. 
 This study is an important contribution towards elucidating a controversial 
topic that inflammation and bone formation are interrelated and could lead to 
subchondral bone sclerosis, which is the first insult to a healthy knee joint.  
The control of (re)modelling requires not only osteoblasts but also osteoclasts. 
This is discussed in the supplementary data, section 7.3. 
5.6 CONCLUSION 
This study shows that low-dose long-term stimulation of TNFα on osteocytes 
could promote bone formation, whereas high-dose has opposing affects in vitro. The 
results also show that there is a synergistic, stronger influence of the observed effect 
when osteocytes and osteoblasts act together and activate the WNT β-catenin 
pathway. The data confirms that a functional relationship exists in the osteocyte-
osteoblast network and that these can regulate differentially under different doses and 
duration of inflammation. Site-specifically targeting the TNFα induced osteocyte-
WNT β-catenin pathway could potentially pave the way to reduce or retard the 
progression of subchondral bone sclerosis in OA.   
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OA, an accepted world health problem, is an organ level failure. From a 
clinical perspective OA leads to joint pain and irreversible loss of function. This 
disease is very heterogeneous and slow to develop but its pathophysiology is 
undoubtedly much more complex than a simple “wear and tear” or aging 
phenomenon. Moreover, many different processes may play a role in the process of 
joint destruction in individual patients. Although there are a number of surgical and 
non-surgical ways to deal with this disease, there is currently no cure or disease 
modifying drugs. A more detailed understanding of cell and molecular factors 
involved in disease progression is required to develop techniques that will identify 
the disease process at an early stage and further develop therapies to prevent or slow 
the progression of this debilitating disease.  
Historically, OA was considered a disease of the cartilage as a result of the 
apparent changes seen on and within the cartilage. However, our current 
understanding highlights the importance of bone in disease progression. Although 
there are chondro-centric and osteo-centric views about the initiation and progression 
of OA in the research community, most researchers will now defend a global and 
integrated view in which OA is viewed as a disease with an interactive role in 
pathology of the whole joint or bone-cartilage unit. An ideal disease treatment should 
target both these tissues.  
Significant research has been conducted on most cells of the joint, however, 
until now, osteocytes have been completely ignored. Therefore, to better understand 
OA it is important to identify specific osteocyte factors responsible for structural 
changes; view their significance in the progression of OA; it may then be possible to 
identify new targets for disease treatment.  
Discoveries in the recent years have changed the idea of osteocytes from 
being passive, metabolically inactive cells to endocrine cells and orchestrators of 
bone remodelling. This represents a paradigm shift in the bone field. Although there 
has been speculation that osteocytes could play a role in OA, this thesis is the first 
attempt to characterise osteocytes in OA and implicate their biological relevance for 
better treatment options.  
This project sought to advance the knowledge in understanding the consistent 
OA clinical finding, subchondral bone sclerosis, with respect to osteocytes. The 
objective being to further investigate and reveal a potential molecular mechanism 
  
Chapter 6 Discussion 129 
involved during this process at in vivo and cellular level in OA pathophysiology. The 
ultimate aim of this project, irrespective of the initiating factor (cartilage or the 
bone), is to draw a biological relevance with the dramatic changes observed in OA 
osteocytes.  
Section 2.6.3 and Chapter 3 highlight some of the discrepancies that exist in 
the research community with respect to subchondral bone volume and 
mineralization. Chapter 3 focuses on human samples. There exist some arguments 
about the subchondral bone being hypo or hyper mineralised and whether there is 
increased or decreased subchondral bone volume to total volume. To reconcile these 
differences in the literature, we characterised the subchondral bone and mineral 
changes using different methods and then characterised the osteocyte changes. We 
used microCT, immunolocalization of bone markers, histology, gene expression and 
western blotting in samples graded according to disease severity. Variables such as 
age and gender  were considered. The findings from this study indicate an increased 
bone volume and hyper mineralization in the subchondral bone of OA patients. In a 
finding not previously reported, in this project, dramatic osteocyte morphological 
differences were observed. We also quantified the expression of disrupted osteocyte 
markers and MMPs. Another interesting finding from this study is that osteocytes are 
TRAP positive around the marrow space, implying that osteocytes could potentially 
direct osteoclastogenisis or participate in bone resorption. Collectively, this data 
shows that osteocytes do change in OA and could play a role in OA 
pathophysiology/subchondral bone sclerosis.  
Although Chapter 3 focuses on human samples and could be considered the 
most biologically relevant results. But tissue was collected from end stage OA 
patients requiring knee replacement surgery. Various factors could trigger the 
complex detrimental cascades of damage seen in OA. As mentioned previously, it is 
very important to identify the disease at the initial phase. The lack of an accurate 
correlation between characteristic clinical features and pathobiological changes of 
human joints has placed in vivo and in vitro studies as the corner stone to explore and 
clarify the molecular pathogenic events that occur at onset and progression of OA 
[116, 216]. Therefore Chapter 4 focused on establishing a suitable animal model, that 
resembles the clinical situation and allows the investigation of progressive osteocyte 
and mineral changes in OA pathophysiology.  
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Rats were chosen due to their similar histopathological features to humans and 
their minimal spontaneous degeneration in knee joints. This is to allow any changes 
in the knee joints to be directly associated to the surgical intervention [217]. OA was 
initially induced by: (1) transecting the anterior cruciate ligament (ACLT group), (2) 
removing the medial meniscus (MSX group); and (3) a single intra articular injection 
of Mono-ido-acetate (MIA). The MIA and ACLT groups were excluded as they 
showed decreased bone volume compared to the SHAM controls at 8 weeks that was 
not consistent with our clinical data. The MSX group showed high subchondral bone 
volume compared to the SHAM controls similar to the human clinical condition 
shown in Chapter 3. The findings from this study correlate to the changes seen in our 
clinical human samples and for the first time, mineral changes and the rate of bone 
remodelling was assessed at 2 time points using flurochrome labels. These results 
indicate that there is a question of balance in bone remodelling where site-specific 
increased bone remodelling was observed with net bone formation and associated 
osteophytes at both time points. Osteocyte changes observed at this time point were 
similar to the changes observed in human samples.  
The OA MSX experimental rat model was shown to resemble the human 
situation more closely and is suitable for study of OA subchondral bone osteocyte 
pathogenesis. The WNT β-catenin signalling pathway has been implicated in OA and 
shown to play an important role in regulating osteocytes to maintain homeostasis. 
Therefore, to gain a mechanistic insight, this signalling pathway was analysed in our 
animal model. Interestingly, osteocytes from the medial compartment showed higher 
WNT activity with a significant reduction in the expression of inhibitors of WNT 
signalling, (DKK1 and SOST). These results are very exciting as activation or 
deactivation of signalling molecules controlling osteocytes hold great potential to be 
high priority targets for novel OA therapies. Supplementary data presented in Figure 
7-2 shows preliminary microCT data and disrupted osteocyte morphology 6 months 
post MSX surgery as opposed to 2 months post surgery that was investigated in 
Chapter 4. 
 Chapter 4 and the supplementary data presents an enormous body of work 
defining mineral changes seen in OA (in vitro, in vivo and clinically), addresses the 
question of bone remodelling and indicates a potential regulatory role of osteocytes 
in subchondral bone remodeling and mineral metabolism during OA pathogenesis.  
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For Chapter 5, in the pursuit to create an OA environment Initially, we used 
conditioned media collected from human OA and control chondrocytes in 3D 
culture, differentiated for 14 days and observed its effect on osteocytes. As expected, 
it did show altered bone remodelling and mineral markers. However, defining this 
OA environment is complex as soluble factors are patient specific. Inflammation, 
considered an old player back in the game, is proposed as a primary driving force for 
the progression of OA associated with subchondral bone sclerosis. On the other 
hand, tumour necrosis factor (TNFα) has an important role not only in inflammatory 
arthritis but also in degenerative joint disease [4]. Anti-TNFα has been shown as a 
potential promising strategy for the treatment of OA [5], however, its mechanisms 
are unexplored and debated. Therefore in Chapter 5 we hypothesised that osteocytes 
could be a key player in this condition. 
 Based on literature and dose dependent changes observed in Figure 5-1, low 
and high doses of TNFα on osteocytes were used. Although cytokines (TNFα) are 
known to be osteoinhibitory in larger doses, interesting and unexpected outcomes 
demonstrated that osteocytes exposed to low-dose long-term inflammation promoted 
bone formation. Another fascinating finding was revealed when the condition media 
from low and high-dose stimulated osteocytes were used to grow osteoblasts. 
Osteoblasts stimulated with conditioned media (from low-dose TNFα stimulated 
osteocytes) promoted bone formation, whereas the inverse promoted bone resorption. 
This implies that different levels of inflammation affect osteocytes potential to create 
a niche in promoting bone formation differently, this effect could potentially 
distinguish OA (characterized by bone formation), from rheumatoid arthritis which is 
characterized by bone resorption. WNT was analysed with results similar to the in 
vivo results. Chapter 5 may support the theory of hormesis where toxins and other 
stressors in low-doses generally promote favourable biological responses. The 
question of whether TNFα promotes subchondral bone sclerosis in OA is difficult to 
answer at this point given the limitations of this study. Whether or not this study 
provides conclusive evidence that TNFα  plays a role in subchondral bone sclerosis 
via osteocyte-WNT β-catenin signalling pathway is dependent upon and to be 
determined by the outcomes and findings of subsequent research on this topic. It may 
be the case that inflammation in fact has a protective effect in OA and that bone 
resorption simply cannot keep pace in a focal site-specific manner. This being said, 
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this study provides an important contribution to elucidating answers to a 
controversial topic that inflammation and bone formation are interrelated and could 
lead to subchondral bone sclerosis, which is the first insult to a healthy knee joint.  
As shown in Chapter 3 and 4, osteocytes are dendritic and have the potential to 
communicate with each other at preferred distances. This could explain inflammation 
induced site specific remodelling. Chapter 5 shows for the first time the effect of 
inflammation on osteocytes and their possible role in subchondral bone sclerosis.  
The human body is the ultimate system, more advanced than any man-made in 
vitro systems/animal models used to study disease progression. It is impossible to 
recreate the dynamic complexities of a joint but it is believed that the experimental 
work presented here provides strong evidence that osteocytes are altered in OA. This 
provides some insight into the molecular mechanisms that control osteocyte induced 
site-specific subchondral bone sclerosis in OA. This study also brings a new 
perspective to the role of low-dose inflammation in this disease. As well as 
answering a number of important questions, this thesis raises a number of further 
questions, the answers to which are unclear. Conclusions are limited by a number of 
factors that are common to investigations of complex biological processes.  
6.1 LIMITATIONS  
In Chapter 3 where subchondral bone characterisation studies were undertaken, 
samples for these studies were collected from the tibial plateau of patients 
undergoing knee replacement surgery. The sclerotic zone of the tibial medial 
compartment was used as the OA sample and the lateral compartment of the same 
patient used as controls. Although this method is well accepted (as OA is very site 
specific), this comparison technique/method is debatable. It would be interesting to 
directly compare the tibial medial compartment generated from normal patients to 
the tibial medial compartment from OA patients. However, it is very difficult to find 
normal samples that are age, gender and disease matched as it would require a very 
large repository of human joint tissues. 
Chapter 3 and 4, showed TRAP positive osteocytes. Although some studies 
have shown the expression of TRAP in osteocytes close to the bone resorbing 
surface, its validity and the role of osteocytes in osteoclastogenisis remains 
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controversial [232]. However the recent publication by Nakashima et al 2011 [92] 
shows that osteocytes have a more potent ability to support osteoclastogenesis than 
osteoblasts. We believe that the TRAP enzymes have diffused from the bone 
resorbing surface through the osteocyte canalicular network under physiological 
conditions and are a true representation of TRAP proteins in the respective 
osteocytes [232]. This implies that osteocytes have the potential to control the 
direction of osteoclastic resorption in OA subchondral bone. 
OA normally takes many decades to develop and is multifactorial. Although 
the MSX rat model is well characterised and widely used to study the detection and 
progression of OA [218, 219], as well as test the efficacy of new therapeutic drugs 
[42, 221], it is not an ideal animal model. For example, humans generally discontinue 
using an affected limb whereas rats do not. Therefore the disease progression is very 
rapid and less amenable to therapeutic intervention in rats. Having said this, there is 
no gold standard model that can be truly defined to represent human aetiology and it 
is important to consider distinct advantages, disadvantages and documented changes 
before implicating it to disease progression and humans. 
Studying osteocytes has been a challenging exercise as explained in section 
2.5.6. The accrual of knowledge has been relatively slow but new technologies and 
models are helping unlock their secrets. One of the major barriers to understanding 
bone physiology at in vitro level is that we lack a methodology to study bone cells in 
their native environment. In our study the differences seen between the two cell types 
(osteoblasts and osteocytes) may be due to species differences. However, MLOY4 is 
a well characterised osteocyte cell line. Although MLOY4 is a well characterised and 
accepted osteocyte cell line, it is proliferating. In our study we have used it in a 2D 
isolated system to mimic a terminally differentiated cell type that lives under the 
influence of other types of cells in a 3D environment. Having said this, immortalised 
cell lines take advantage of genetic instabilities in cells that have been cultured from 
pathological sources; and cell culture methods have an advantage of defining culture 
conditions in a controlled environment.  
6.2 FUTURE DIRECTIONS 
It is clear that this body of work leaves many questions unanswered. However 
it is the first attempt to characterise osteocytes in OA, evaluate the osteocyte-WNT 
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signalling pathway and its involvement in OA and determine the role of low-dose 
inflammation in this disease. Upon this background more detailed studies will be 
established providing further insights into this subject. It would be of great interest to 
test osteocyte site-specific inhibition of WNT activity in OA progression using 
DMP1 cre-conditional knock-out animals. It would be exciting to understand TNFα 
binding to its receptors and its role in the WNT signalling pathway because, binding 
TNFα to TNFR1 is considered to be an irreversible mechanism. Conversely TNFα 
binding to TNFR2 is considered both rapid on and off kinetics. However less is 
known about the mechanisms of signal transduction and biological function of these 
receptors. It is also tempting, based on the in vitro studies, to target low-dose 
inflammation and its implications to treat OA. In the last decade, the discovery of 
osteocyte potential to effect cells and tissues far beyond the bone suggests that the 
research community has only scratched the surface of what the osteocyte is capable 
of. Although osteocyte biology has represented a paradigm shift in the bone field, 
there are a number of unanswered questions (See Chapter 7,  page 148 and 
interesting resin filled, acid etched SEM images from pages 149-154 suggesting a 
number of possible roles for osteocytes) that could help researchers target osteocytes 
in therapeutics for bone dysplasia and possibly have therapeutic potential in disorders 
like sarcopenia and even chronic kidney failure. 
6.3 CONCLUDING REMARKS 
In conclusion, I believe that, although we have opened new doors to new 
possibilities of targeting osteocytes as a therapeutic cure for OA, one sole approach 
will not be a panacea for OA. Keeping in mind the medical economics and medical 
ethics, the cure for OA would be at the crossroads of interdisciplinary medicine 
ultimately leading to the better management of OA. Although the results presented in 
this thesis are a collection of three years of research, in retrospect, significant work is 
needed before the findings in this thesis can be applied clinically. Further 
investigations will bring us a step closer towards improving the quality of life for 
millions of OA patients worldwide. 
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7.1 SUBCHONDRAL BONE CHANGES IN RATS INDUCED WITH OA 
FOR 6 MONTHS 
 
Figure 7-1 Representative microCT reconstructions of SHAM controls and MSX rats, 2 and 6 
months post medial minesectomy surgery 
 
(a) Representative microCT reconstructions of SHAM and MSX rats, 2 months post surgery shows, 
joint space narrowing, osteophyte formation at the margins of the joint.(red arrows) Subchondral bone 
sclerosis in the medial side of MSX rats (yellow arrows) and well preserved corresponding 
subchondral bone area in SHAM controls (b) Representative microCT reconstructions of SHAM and 
MSX rats, 6 months post surgery. Apart from joint space narrowing and osteophyte formation (red 
arrows), growth plate fusion was observed not only in MSX rats but also in SHAM controls (green 
arrows) that was not observed 2 months post surgery. The sclerotic area (yellow arrows) was not only 
localised to the medial compartment but had progressed to the lateral compartment.  
 
(a)  
(b) 
Coronal view of knee joint                  Tibial coronal view            Tibial axial view 
SHAM 
SHAM 
MSX 
MSX 
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Figure 7-2 Acid etched tibial bone surface (coronal section) showing morphology of osteocytes in 
SHAM controls and MSX rats 6 months post surgery 
(a) Shows Representative SEM SHAM control image showing well preserved subchondral bone area. 
(c) Shows the morphology of osteocytes in SHAM controls to be well aligned, spindle shaped and 
preserved dendrites. (b) Shows subchondral bone thickening in MSX OA (d) represents altered 
osteocyte morphology and broken dendrites.  
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7.2 ROLE OF OSTEOCYTE IN OSTEOCLASTOGENESIS IN A LOW-
DOSE INFLAMMATORY ENVIRONMENT 
 
The control of (re)modelling requires not only osteoblasts but also osteoclasts. 
Recent research demonstrates that osteocytes can orchestrate osteoclastic resorption 
through the expression of RANK ligand (RANKL). It also demonstrates that the 
influence of osteocytes is greater than that of osteoblasts - a role that has previously 
been known to be played by osteoblasts to a larger extent [92]. This study  (chapter 
5) observed the expression of RANKL to be significantly higher in osteocytes 
stimulated with low-dose TNFα compared to controls and high-dose TNFα with a 
stronger effect in  co-culture studies (Figure 7-3). The outcomes of this could 
potentially provide justification for  the increased bone (re)modelling and associated 
net bone formation in OA patients compared to controls. However, this is debatable 
given that osteocytes are conventionally considered to function down-stream to 
osteoblasts, which subsequently fails to explain the coupling of bone formation and 
bone resorption. To further support this, recent findings by Yeong et al presented at 
the ANZBMS 2013 conference, demonstrated through highly purified osteocyte cells 
via fluorescence activated cell sorting (FACS), that it is in fact osteoblasts that 
produce more RANKL than osteocytes. Nonetheless, this study focuses on 
osteogenesis and requires further mechanistic studies and validations before it is 
applied to any in vitro or in vivo setting.  
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Figure 7-3 Effect of TNFα on MLOY4/osteocytes on RANKLgene expression 
 
(a,i) Effect of low-dose TNFα on MLOY4/osteocytes on RANL gene expression. (a, ii) Effect of high-
dose TNFα on MLOY4/osteocytes on RANL gene expression.  For i & ii, relative gene expression 
normalised to β-actin represented as fold change to its control.(c) Gene expression of RANKL from 
condition media experiments. Relative gene expression normalised to GAPDH represented as fold 
change to day1 control. Refer Chapter 5 for experimental set up and methods.  
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